<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id>
<journal-title>Frontiers in Aging Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Aging Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1663-4365</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnagi.2021.695718</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Modeling Parkinson&#x02019;s Disease: Not Only Rodents?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shadrina</surname> <given-names>Maria</given-names></name>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/321268/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Slominsky</surname> <given-names>Petr</given-names></name>
<uri xlink:href="https://loop.frontiersin.org/people/381311/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><institution>Laboratory of Molecular Genetics of Hereditary Diseases, Institute of Molecular Genetics of National Research Centre &#x0201C;Kurchatov Institute&#x0201D;</institution>, <addr-line>Moscow</addr-line>, <country>Russia</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Ralf J. Braun, Danube Private University, Austria</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Christian Johannes Gloeckner, Helmholtz Association of German Research Centers (HZ), Germany; Andreas Aufschnaiter, Stockholm University, Sweden</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Maria Shadrina <email>shadrina&#x00040;img.ras.ru</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>08</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>13</volume>
<elocation-id>695718</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>04</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>06</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2021 Shadrina and Slominsky.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Shadrina and Slominsky</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract><p>Parkinson&#x02019;s disease (PD) is a common chronic progressive multifactorial neurodegenerative disease. In most cases, PD develops as a sporadic idiopathic disease. However, in 10%&#x02013;15% of all patients, Mendelian inheritance of the disease is observed in an autosomal dominant or autosomal recessive manner. To date, mutations in seven genes have been convincingly confirmed as causative in typical familial forms of PD, i.e., <italic>SNCA, LRRK2, VPS35, PRKN, PINK1, GBA</italic>, and <italic>DJ-1</italic>. Family and genome-wide association studies have also identified a number of candidate disease genes and a common genetic variability at 90 loci has been linked to risk for PD. The analysis of the biological function of both proven and candidate genes made it possible to conclude that mitochondrial dysfunction, lysosomal dysfunction, impaired exosomal transport, and immunological processes can play important roles in the development of the pathological process of PD. The mechanisms of initiation of the pathological process and its earliest stages remain unclear. The study of the early stages of the disease (before the first motor symptoms appear) is extremely complicated by the long preclinical period. In addition, at present, the possibility of performing complex biochemical and molecular biological studies familial forms of PD is limited. However, in this case, the analysis of the state of the central nervous system can only be assessed by indirect signs, such as the level of metabolites in the cerebrospinal fluid, peripheral blood, and other biological fluids. One of the potential solutions to this problem is the analysis of disease models, in which it is possible to conduct a detailed in-depth study of all aspects of the pathological process, starting from its earliest stages. Many modeling options are available currently. An analysis of studies published in the 2000s suggests that toxic models in rodents are used in the vast majority of cases. However, interesting and important data for understanding the pathogenesis of PD can be obtained from other <italic>in vivo</italic> models. Within the framework of this review, we will consider various models of PD that were created using various living organisms, from unicellular yeast (<italic>Saccharomyces cerevisiae</italic>) and invertebrate (<italic>Nematode</italic> and <italic>Drosophila</italic>) forms to various mammalian species.</p></abstract>
<kwd-group>
<kwd>Parkinson&#x02019;s disease</kwd>
<kwd>pathogenesis</kwd>
<kwd><italic>in vivo</italic> models</kwd>
<kwd>toxic models</kwd>
<kwd>genetic models</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="183"/>
<page-count count="18"/>
<word-count count="15864"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="introduction" id="s1">
<title>Introduction</title>
<p>Parkinson&#x02019;s disease (PD) is a common chronic progressive multifactorial neurodegenerative disease that affects at least 1% of people over the age of 65 and at least 4% of people over the age of 80 (Elbaz et al., <xref ref-type="bibr" rid="B42">2016</xref>). It is characterized by the classic tetrad of motor symptoms (bradykinesia, resting tremor, rigidity, postural instability). However, in recent years, the diagnostic criteria for the disease have been refined, and postural instability is not among the obligative criteria for PD (Postuma et al., <xref ref-type="bibr" rid="B128">2015</xref>). Motor symptoms are associated with impaired dopamine synthesis in the pars compacta substantia nigra as a result of the death of dopaminergic neurons and a decrease in the level of this neurotransmitter in the striatum. At the same time, it is believed that the appearance of motor symptoms is observed only with a very significant decrease in dopamine levels&#x02014;up to 70&#x02013;80% of the norm. The appearance of the first motor symptoms is preceded by a number of non-motor features (Jankovic, <xref ref-type="bibr" rid="B72">2008a</xref>,<xref ref-type="bibr" rid="B73">b</xref>). These include, first of all, constipation associated with impaired motility of the large intestine, rapid eye movement sleep behavior disorder (RBD), impaired sense of smell, anxiety disorders, and anemia (Savica et al., <xref ref-type="bibr" rid="B139">2010</xref>). These non-motor symptoms appear 15&#x02013;20 years before the onset of motor symptoms. Non-motor symptoms are nonspecific, which prevents them from being used for the diagnosis of PD.</p>
<p>A typical pathological sign for PD is Lewy bodies and Lewy neurites&#x02014;intracellular inclusions, the main component of which is the alpha-synuclein protein. A detailed analysis of these inclusions showed that the first such inclusions are formed long before the onset of the motor phase of the disease&#x02014;at stages 1&#x02013;2 according to Braak&#x02019;s classification (Braak et al., <xref ref-type="bibr" rid="B16">1998</xref>, <xref ref-type="bibr" rid="B18">2000</xref>, <xref ref-type="bibr" rid="B17">2004</xref>). At these stages, these inclusions are detected in the central nervous system in the dorsal motor nucleus, nucleus ambiguous, solitary nucleus, dorsal raphe nucleus, gigantocellular nucleus, olfactory bulbs, as well as in some types of intestinal neurons (for example, in the Auerbach plexus). Only at the third stage (also non-motor) Lewy bodies and Lewy neurites are detected in the substantia nigra, and at stages 4&#x02013;6 they are detected in other areas of the nigrostriatal system, the mesocortex and the somato-sensory cortex (Braak et al., <xref ref-type="bibr" rid="B17">2004</xref>). The concept of ascending development of lesions of the nervous system and frequent impairment of intestinal motility in the preclinical stage of PD have drawn attention to the important role of the gastrointestinal tract as a site of occurrence of the first inclusions of alpha-synuclein (Edwards et al., <xref ref-type="bibr" rid="B41">1992</xref>; Braak et al., <xref ref-type="bibr" rid="B15">2006</xref>; S&#x000E1;nchez-Ferro et al., <xref ref-type="bibr" rid="B137">2015</xref>; Ambrosini et al., <xref ref-type="bibr" rid="B2">2019</xref>). The gut microbiome may play an important role in the formation of the first alpha-synuclein inclusion bodies (Yang et al., <xref ref-type="bibr" rid="B174">2019</xref>; Elfil et al., <xref ref-type="bibr" rid="B43">2020</xref>).</p>
<p>In most cases, PD develops as a sporadic idiopathic disease. However, in 10&#x02013;15% of all patients, mendelian inheritance of the disease is observed in an autosomal dominant or autosomal recessive type. It should be noted that according to the clinical picture, the sporadic and hereditary forms of the disease are practically indistinguishable. The first mutations in the familial form of PD were identified in 1997 in the alpha-sinulein gene <italic>SNCA</italic> (Polymeropoulos et al., <xref ref-type="bibr" rid="B127">1997</xref>). To date, mutations in seven genes have been convincingly confirmed as causative in typical familial forms of PD, i.e., <italic>SNCA, LRRK2, VPS35, PRKN, PINK1, GBA</italic>, and <italic>DJ-1</italic>. Family and genome-wide association studies have also identified a number of candidate genes and common genetic variability at 90 loci, which have been associated with the risk of development of PD (Bandres-Ciga et al., <xref ref-type="bibr" rid="B7">2020</xref>). Confirmation of the pathogenetic role of these requires further research. However, analysis of the biological function of both proven and candidate genes made it possible to conclude that mitochondrial dysfunction (Billingsley et al., <xref ref-type="bibr" rid="B13">2019</xref>), lysosomal dysfunction, and impaired exosomal transport play an important role in the development of the pathological process (Bandres-Ciga et al., <xref ref-type="bibr" rid="B8">2019</xref>, <xref ref-type="bibr" rid="B7">2020</xref>). Immunological processes can play an important role in the development of the disease&#x02014;this is evidenced by the association with the development of the disease of polymorphic variants in the BST1 gene and the HLA gene cluster. There is a hypothesis that it is immunological factors that can determine the predominant death of dopaminergic neurons (Billingsley et al., <xref ref-type="bibr" rid="B12">2018</xref>).</p>
<p>However, despite all the successes achieved in the study of the pathogenesis of PD, the question of the mechanisms of initiation of the pathological process and its earliest stages remains unresolved. Understanding these mechanisms is necessary for the development of methods for the early preclinical diagnosis of the disease, as well as for the search for new approaches to pathogenetic therapy (Lotankar et al., <xref ref-type="bibr" rid="B93">2017</xref>; Tarakad and Jankovic, <xref ref-type="bibr" rid="B152">2017</xref>). The study of the early stages of the disease (before the first motor symptoms appear) is extremely complicated by the long preclinical period and the features of the pathology associated with damage to various parts of the central nervous system. In addition, at present, the possibility of conducting complex biochemical and molecular biological studies in persons with a reliably established risk of developing PD is limited. In fact, such an analysis can only be carried out in carriers of pathogenetically significant mutations in the genes of familial forms of PD. However, in this case, the analysis of the state of the central nervous system can only be assessed by indirect signs, such as the level of metabolites in the cerebrospinal fluid, peripheral, blood and other biological fluids.One of the possible solutions to the problem is the analysis of disease models, in which it is possible to conduct a detailed in-depth study of all aspects of the pathological process, starting from its earliest stages. A lot of modeling options are offered (Dauer and Przedborski, <xref ref-type="bibr" rid="B37">2003</xref>; Danek et al., <xref ref-type="bibr" rid="B35">2017</xref>; Ghatak et al., <xref ref-type="bibr" rid="B59">2018</xref>; Kin et al., <xref ref-type="bibr" rid="B76">2019</xref>; Chia et al., <xref ref-type="bibr" rid="B28">2020</xref>). An analysis of studies published in the 2,000 s suggests that toxic models in rodents are used in the vast majority of cases (Kin et al., <xref ref-type="bibr" rid="B76">2019</xref>). However, interesting and important data for understanding the pathogenesis of PD can be obtained from other <italic>in vivo</italic> models. Within the framework of this review, we will consider various models of PD, created using various living organisms&#x02014;from unicellular [yeast (<italic>S. cerevisiae</italic>) and invertebrates (<italic>Nematode</italic>, <italic>Drosophila</italic>) to various mammalian species].</p>
</sec>
<sec id="s2">
<title>Yeast Models: What Could Be Simpler?</title>
<p>Modeling of various pathological diseases in yeast cells has been actively developing since the last third of the 20th century (Mortimer, <xref ref-type="bibr" rid="B112">2000</xref>). This type of model is aimed at studying the biological functions of the proteins associated with the development of monogenic forms of hereditary diseases and is based on the use of two main strategies. The first strategy consists of the heterologous expression of the genes of monogenic diseases (both wild-type genes and their mutant variants) in yeast cells. The second strategy entails the analysis of the functional activity in yeast cells of orthologous genes of pathologically significant human genes (Tenreiro and Outeiro, <xref ref-type="bibr" rid="B155">2010</xref>; Dunham and Fowler, <xref ref-type="bibr" rid="B40">2013</xref>). A combination of different approaches is also possible, e.g., the combination of the analysis of the orthologous gene of one of the disease genes with the heterologous expression of another pathogenetically significant gene (Menezes et al., <xref ref-type="bibr" rid="B108">2015</xref>). Both of these strategies have been widely used in the study of genes responsible for monogenic forms of PD, i.e., the heterologous expression has been widely used for the analysis of the genes encoding the proteins parkin, PINK1, LRRK2, and alpha-synuclein. Orthologous gene analysis has also been used to study the biological function of human genes, such as <italic>DJ-1</italic>, <italic>VPS35</italic>, <italic>EIF4G1</italic>, and <italic>ATP13A2</italic>.</p>
<p>Alpha-synuclein is one of the proteins associated with the development of PD that has been most actively studied using yeast models. Concomitantly, it was shown that heterologous expression of the <italic>SNCA</italic> gene in yeast cells (in which there is no homologous gene) leads to a cytotoxic effect. The severity of this effect is determined by the level of expression of the <italic>SNCA</italic> transgene and the characteristics of the recipient yeast strain (Outeiro and Lindquist, <xref ref-type="bibr" rid="B120">2003</xref>; Willingham et al., <xref ref-type="bibr" rid="B170">2003</xref>). This cytotoxic effect is associated with the formation of intracellular inclusions, which are amyloid-like structures consisting of fibrillar alpha-synuclein, or the formation of vesicular inclusions (Soper et al., <xref ref-type="bibr" rid="B146">2008</xref>). The formation of inclusion bodies leads to the disruption of various cellular processes, mainly the interaction of the endoplasmic reticulum with the Golgi complex, mitochondrial biogenesis, the functioning of proteasomes, mitophagy, and autophagy (Chen et al., <xref ref-type="bibr" rid="B26">2005a</xref>,<xref ref-type="bibr" rid="B27">b</xref>; Dunham and Fowler, <xref ref-type="bibr" rid="B40">2013</xref>; Menezes et al., <xref ref-type="bibr" rid="B108">2015</xref>).</p>
<p>The important role of molecular chaperones in the development of alpha-synuclein toxicity was demonstrated using yeast models. It was found that the activation of the expression of genes encoding heat-shock proteins reduces the toxicity of alpha-synuclein aggregates, while the deletion of genes encoding individual chaperones increases their toxicity (Flower et al., <xref ref-type="bibr" rid="B53">2005</xref>; Liang et al., <xref ref-type="bibr" rid="B88">2008</xref>; Gade et al., <xref ref-type="bibr" rid="B55">2014</xref>). The role of heat-shock proteins in the degradation of fibrillar alpha-synuclein was confirmed <italic>in vitro</italic> (Gao et al., <xref ref-type="bibr" rid="B57">2015</xref>). Altered expression of the <italic>HSC70</italic> gene and several other genes encoding molecular chaperones was shown in the substantia nigra in patients with PD (Mandel et al., <xref ref-type="bibr" rid="B97">2005</xref>; Gr&#x000FC;nblatt et al., <xref ref-type="bibr" rid="B63">2018</xref>).</p>
<p>Genetic screening technologies using yeast models have shown that a very large number of biological processes modulate the toxicity of alpha-synuclein inclusions. Thus, the role of mitochondrial and proteasome dysfunction in alpha-synuclein-mediated cytotoxicity was confirmed. More than 80 new genes have also been identified that contribute to this type of toxicity. These genes have been associated with vesicular transport, lipid metabolism, ergosterol synthesis, and response to stress by the mTOR signaling pathway (Liang et al., <xref ref-type="bibr" rid="B88">2008</xref>; Yeger-Lotem et al., <xref ref-type="bibr" rid="B176">2009</xref>; B&#x000FC;ttner et al., <xref ref-type="bibr" rid="B20">2013</xref>; Hogg and Prehn, <xref ref-type="bibr" rid="B65">2013</xref>). This significantly expanded our understanding of the possible role of alpha-synuclein in cells. However, the question remains as to how certain interactions between alpha-synuclein and other proteins/metabolic pathways play a role in the development of PD. The interactions identified in yeast models should be confirmed in other models of the disease and in patients with PD. A striking example of such a transition is the role of proteins of the VPS family (VPS24, VPS28, and VPS60) in reducing the toxicity of alpha-synuclein by controlling the sorting of proteins in the Golgi complex during the formation of endosomes and prevacuoles, which was first revealed in a yeast model (Liang et al., <xref ref-type="bibr" rid="B88">2008</xref>) and was later confirmed by the detection of mutations in the gene encoding the VPS35 protein (a homolog of the yeast VPS35 protein) in one of the familial monogenic forms of PD, PARK17 (Vilari&#x000F1;o-G&#x000FC;ell et al., <xref ref-type="bibr" rid="B161">2011</xref>; Zimprich et al., <xref ref-type="bibr" rid="B182">2011</xref>; Ando et al., <xref ref-type="bibr" rid="B3">2012</xref>).</p>
<p>Another aim of using yeast models with the formation of alpha-synuclein aggregates is the search for compounds that reduce the aggregation of alpha-synuclein monomers and/or the toxicity of the formed aggregates. The first such work was carried out by Su et al. (<xref ref-type="bibr" rid="B150">2010</xref>), in which the screening of a library of 115,000 compounds revealed a group of chemically related compounds of the 1,2,3,4-tetrahydroquinolinone family that reduced the formation of alpha-synuclein aggregates in yeast cells, followed by the normalization of transport between the Golgi complex and the endoplasmic reticulum and mitochondrial function. It should be noted that these compounds were active in preventing the formation of alpha-synuclein fibrils in other models, both <italic>in vitro</italic> (nematode neurons and rat midbrain neurons) and <italic>in vivo</italic> (toxic rotenone model of PD in rodents). These works led to the identification of a large number of compounds with a different chemical nature that reduce the toxicity of alpha-synuclein; i.e., mannosylglycerate (Faria et al., <xref ref-type="bibr" rid="B45">2013</xref>), Latrepirdine (Dimebon; dimebolin) (Steele et al., <xref ref-type="bibr" rid="B149">2013</xref>), several cyclic peptides (Kritzer et al., <xref ref-type="bibr" rid="B79">2009</xref>), cerium oxide nanoparticles (Ruotolo et al., <xref ref-type="bibr" rid="B135">2020</xref>), flavonoids, (poly)phenols, plant catechins [for example, from the leaves of <italic>Arbutus unedo L</italic>. (strawberry tree) and (green tea; Griffioen et al., <xref ref-type="bibr" rid="B62">2006</xref>; Williams et al., <xref ref-type="bibr" rid="B169">2007</xref>; Macedo et al., <xref ref-type="bibr" rid="B96">2018</xref>), and yeast red pigment (a polymer of 1-(5-phosphoribosyl)-5-aminoimidazole; Nevzglyadova et al., <xref ref-type="bibr" rid="B114">2018</xref>)]. The methodology used in this type of research is rapidly developing, and the use of new screening systems for bioactive compounds in yeast (Br&#x000E1;s et al., <xref ref-type="bibr" rid="B19">2019</xref>) will allow the identification of new low-molecular-weight compounds&#x02014;blockers of the formation of protein aggregates.</p>
<p>One of the main genes of the familial form of Parkinson&#x02019;s disease is the <italic>LRRK2</italic> gene, which encodes a leucine-rich protein kinase, dardarin. Mutations in this gene lead to the development of an autosomal dominant form of the disease and are associated with the formation of toxic gain-of-function variants of LRRK2 protein, which, in particular, were confirmed by the expression of various truncated variants of LRRK2 protein in yeast cells (Xiong et al., <xref ref-type="bibr" rid="B173">2010</xref>). On the other hand, the LRRK2 protein can influence mitochondrial biogenesis in yeast cells. It has been shown that an increased level of this protein leads to a decrease in the level of de novo mitochondrial biogenesis and, thereby, to a decrease in the number of mitochondria in aging yeast cells (Aufschnaiter et al., <xref ref-type="bibr" rid="B4">2018</xref>). A change in the number of mitochondria is also observed during the expression of various mutant variants of LRRK2 protein, which leads to an increase in the sensitivity of cells to hydrogen peroxide in yeast cells (Pereira et al., <xref ref-type="bibr" rid="B122">2014</xref>). Thus, modeling in yeast made it possible to reveal important aspects of the functioning of LRRK2 protein and to reveal the key functions of this kinase (Seegobin et al., <xref ref-type="bibr" rid="B140">2020</xref>).</p>
</sec>
<sec id="s3">
<title>Modeling in Invertebrates: Simple Or Not</title>
<sec id="s3-1">
<title>Fruit Fly (<italic>Drosophila</italic>)</title>
<p>The advantages of the fruit fly as a model for studying various biological processes, including pathological ones, are obvious (Shulman et al., <xref ref-type="bibr" rid="B144">2003</xref>; Bilen and Bonini, <xref ref-type="bibr" rid="B11">2005</xref>; Freeman, <xref ref-type="bibr" rid="B54">2015</xref>; McGurk et al., <xref ref-type="bibr" rid="B107">2015</xref>; Zirin et al., <xref ref-type="bibr" rid="B183">2020</xref>): (1) its short life span (about 1 month at an optimal temperature) which allows the tracing of pathological processes throughout ontogenesis; (2) its rapid sexual maturation and the ability quickly to generate a large number of progeny, which speed up the experiments; (3) its relatively small and well-studied genome and the availability of a large panel of methods for manipulating the fruit fly genome; (4) a large collection of fruit fly lines with various mutations; and (5) the conservatism of metabolic pathways and a similar organization of the nervous system (the presence of various types of glial and neuronal cells and the presence of a blood-brain barrier).</p>
<p>However, the nervous system of <italic>Drosophila melanogaster</italic> is not a complete analog of the human nervous system. A striking example of such differences is the alpha-synuclein protein. The gene that encodes this protein is actively expressed in the human nervous system, while an ortholog of the <italic>SNCA</italic> gene has not been found in the <italic>Drosophila</italic> genome. However, even in this case, the formation of inclusion bodies similar to Lewy bodies, the selective death of dopaminergic neurons, and locomotor disorders are observed in neuronal cells in flies that are transgenic for the human <italic>SNCA</italic> gene (Feany and Bender, <xref ref-type="bibr" rid="B47">2000</xref>; Auluck et al., <xref ref-type="bibr" rid="B6">2002</xref>, <xref ref-type="bibr" rid="B5">2010</xref>; Chen and Feany, <xref ref-type="bibr" rid="B25">2005</xref>). These processes are observed both regarding the expression of the wild-type <italic>SNCA</italic> gene and the expression of mutant forms of the <italic>SNCA</italic> gene with the missense mutations (A53T and A30P) identified in patients with the familial PARK1 form of PD (Lee et al., <xref ref-type="bibr" rid="B83">2002</xref>; Dalf&#x000F3; et al., <xref ref-type="bibr" rid="B34">2004</xref>). The death of neuronal cells is observed even when the <italic>SNCA</italic> transgene is expressed only in glial cells. Transgene expression in both neurons and glial cells leads to more severe dopaminergic dysfunction (Olsen and Feany, <xref ref-type="bibr" rid="B118">2019</xref>).</p>
<p>Subsequently, genetic modeling was carried out for other hereditary forms of PD caused by mutations in the <italic>PRKN</italic> (parkin), <italic>PINK1</italic>, <italic>LRRK2</italic>, <italic>VPS35</italic>, <italic>GBA</italic> (beta-glucocerebrosidase), and <italic>DJ-1</italic> genes. Thus, a null mutation in the ortholog of the <italic>PRKN</italic> gene in <italic>Drosophila</italic> led to the disruption of locomotor activity and structural disorders in dopaminergic neurons. However, unlike humans, this <italic>Drosophila</italic> model also exhibited male sterility and myofilament apoptosis, which are caused by mitochondrial dysfunction (Greene et al., <xref ref-type="bibr" rid="B61">2003</xref>; Pesah et al., <xref ref-type="bibr" rid="B123">2004</xref>).</p>
<p>Later, it was shown that this effect may be associated with the activation of the JNK signaling pathway upon knockout of the <italic>PRKN</italic> gene, leading to the death of dopaminergic neurons (Cha et al., <xref ref-type="bibr" rid="B24">2005</xref>). Conversely, pronounced mitochondrial dysfunction is associated with a decrease in mitophagy; in turn, parkin plays an important role in the induction of mitophagy (Cackovic et al., <xref ref-type="bibr" rid="B21">2018</xref>).</p>
<p>A similar phenotype with a combination of male sterility, apoptotic death of muscle cells, and impaired mitochondrial morphology was detected in <italic>Drosophila</italic> with knockout of the ortholog of another PD gene, <italic>PINK1</italic> (Clark et al., <xref ref-type="bibr" rid="B30">2006</xref>; Park et al., <xref ref-type="bibr" rid="B121">2006</xref>; Yang et al., <xref ref-type="bibr" rid="B175">2006</xref>). At the same time, a double knockout of the genes of the pink1 and parkin proteins led to a phenotype that was characteristic of the deletion of each of these genes separately. Conversely, overexpression of the <italic>PRKN</italic> gene minimized the consequences of the knockout of the <italic>PINK1</italic> gene, which indicates the participation of these genes in the same signaling pathway. It was later shown that the pink1 kinase activates parkin by its phosphorylation and the phosphorylation of ubiquitin. Activated parkin suppresses the mitochondrial adapter protein Miro in <italic>Drosophila</italic>, thereby reducing the activity of transport processes in mitochondria (Imai, <xref ref-type="bibr" rid="B69">2020</xref>). The impairment of pink1 function can be at least partially normalized by various natural compounds, e.g., ginseng proteins (Liu et al., <xref ref-type="bibr" rid="B91">2020</xref>).</p>
<p>Knockout models were obtained in <italic>Drosophila</italic> for the ortholog of the <italic>LRRK2</italic> gene (Lee et al., <xref ref-type="bibr" rid="B84">2007</xref>). The deletion of this orthologous gene led to a decrease in locomotor activity, a decrease in tyrosine hydroxylase activity, and degeneration of dopaminergic neurons. Concomitantly, mutations of this type do not reproduce the real autosomal dominant missense mutations in <italic>LRRK2</italic> associated with PD. In this context, using the GAL4/UAS system, <italic>Drosophila</italic> lines were obtained that expressed the wild-type human <italic>LRRK2</italic> gene or carried the G2019S mutation in neuronal cells. Such transgenic flies exhibited degeneration of dopaminergic neurons, locomotor disturbances, and a decrease in life span, and these effects are more pronounced in transgenic flies carrying the G2019S mutation (Liu et al., <xref ref-type="bibr" rid="B92">2008</xref>). The effects of the <italic>LRRK2</italic> transgene are highly dependent on the fly lines used for its expression, the genetic constructs, and specific mutations in the <italic>LRRK2</italic> gene. In different experiments, the effect of overexpression of the normal or mutant <italic>LRRK2</italic> gene on the phenotype is quite different (Imai et al., <xref ref-type="bibr" rid="B70">2008</xref>; Venderova et al., <xref ref-type="bibr" rid="B158">2009</xref>).</p>
<p>Imai et al. (<xref ref-type="bibr" rid="B70">2008</xref>) reported an analysis of the effect of the interaction between genetic and environmental factors in the development of PD. It was shown that the rotenone toxin enhances the development of the neurodegenerative process in <italic>Drosophila</italic> carrying the <italic>LRRK2</italic> transgene. However, it should be noted that, in general, studies of modeling of the sporadic form of the disease using the rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxins are not widespread. This may be attributed to the difficulties in estimating the real dose of the toxin obtained in the simulation. Nevertheless, it was shown that (as in rodents) all of the toxins mentioned above reproduced the main features of PD, i.e., a decrease in locomotor activity and selective death of dopaminergic neurons (Coulom and Birman, <xref ref-type="bibr" rid="B32">2004</xref>; Abolaji et al., <xref ref-type="bibr" rid="B1">2018</xref>). These disorders are caused by oxidative stress resulting from the action of toxins, which can be partially stopped by antioxidants such as melatonin and resveratrol. Thus, toxic models in the future can be used to search for new antiparkinsonian drugs, provided that the methods of toxin introduction are standardized (Liu et al., <xref ref-type="bibr" rid="B91">2020</xref>).</p>
</sec>
<sec id="s3-2">
<title>Nematode <italic>C. elegans</italic></title>
<p>The roundworm nematode has recently been widely used to study various biological processes. Similar to <italic>Drosophila</italic>, it is characterized by a short life span, a quick change of generations with a large number of progeny, ease of cultivation, and a relatively small and well-studied genome that is highly homologous to the human genome, as 40%&#x02013;50% of all protein-coding nematode genes have orthologs in the human genome, including the orthologs of several genes that cause monogenic forms of PD (<italic>LRRK2/lrk-1</italic>, <italic>PINK1/pink-1</italic>, <italic>PRKN/pdr-1</italic>, <italic>DJ-1/djr-1.1/djr-1.2</italic>, and <italic>ATP13A2/catp-6</italic>). However, similar to that observed in <italic>Drosophila</italic>, an ortholog of the SNCA gene was not found in the nematode genome. Moreover, the introduction of the human SNCA transgene into <italic>C. elegans</italic> allows the modeling of the development of synucleinopathy. The genetic engineering methods used for working with the nematode genome are well established. For example, in the nematode, RNA interference methods are well developed, allowing the quick generation of a knockdown model of any gene of interest. For this, the transgene encoding the corresponding siRNA is introduced into the genome of the bacterial cells on which the nematode grows. Other methods of RNA interference have also been developed, including those that allow the tissue-specific knockdown of a gene of interest in a specific type of cell, e.g., in dopaminergic neurons (Firnhaber and Hammarlund, <xref ref-type="bibr" rid="B52">2013</xref>). Working with <italic>C. elegans</italic> is also facilitated by the presence of a large collection of mutant nematode lines (at the Caenorhabditis Genetics Center<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref>, where more than 20,000 strains have been deposited, including genetically modified strains and those expressing the fluorescent proteins GFP and YFP) and the ability quickly to obtain homozygous specimens for mutations in several genes of nematode lines because of their hermaphroditism (Dexter et al., <xref ref-type="bibr" rid="B39">2012</xref>; Cooper and Van Raamsdonk, <xref ref-type="bibr" rid="B31">2018</xref>).</p>
<p>The very high stability of the cellular structure of the nematode <italic>C. elegans</italic> is extremely important. Each hermaphroditic adult consists of exactly 959 somatic cells, 302 of which are nerve cells, which have been characterized in detail regarding their function and synaptic contacts using dopamine, serotonin, glutamate, and acetylcholine as neurotransmitters, as well as GABA.</p>
<p>The nematode is optically highly transparent, which allows the use of fluorescent proteins as trackers for individual genes, cells, or groups of cells, for the <italic>in vivo</italic> monitoring of their activity. Methods for the analysis of dopaminergic neuron dysfunctions in nematodes based on the analysis of worm mobility after starvation of varying duration have been developed and are termed &#x0201C;basal slowing response&#x0201D; and &#x0201C;enhanced slowing response.&#x0201D; Several other behavioral phenotypes have been proposed for analyzing the behavior of nematodes in the context of PD modeling, such as chemotaxis, area-restricted search behavior, swim-to-crawl transition, Dauer-dependent behavior, mechanosensory responses, fecundity, and rate of defecation (Maulik et al., <xref ref-type="bibr" rid="B105">2017</xref>). In recent years, highly accurate methods have been developed for the analysis of motor activity and other aspects of nematode behavior based on the use of microfluidic technologies (Calahorro and Ruiz-Rubio, <xref ref-type="bibr" rid="B22">2011</xref>; Wolozin et al., <xref ref-type="bibr" rid="B172">2011</xref>; Dexter et al., <xref ref-type="bibr" rid="B39">2012</xref>; Youssef et al., <xref ref-type="bibr" rid="B177">2019</xref>).</p>
<p>The processes associated with the expression of the human <italic>SNCA</italic> transgene have been most actively studied (as in the case of <italic>Drosophila</italic>) in the nematode model. Several models overexpressing this wild-type gene (including those in which the gene is fused with the genes of the fluorescent proteins GFP or YFP) and gene variants with pathogenetically significant missense mutations under the control of different promoters specific for dopaminergic neurons and muscle cells have been reported.</p>
<p>It has been shown that some transgenic constructs in nematodes cause a selective decrease in the activity and death of dopaminergic neurons with the formation of inclusions of fibrillar alpha-synuclein, similar to Lewy bodies, in muscle cells. With age, these manifestations intensify (which is characteristic of PD) as the imbalance of protein homeostasis increases as the result of vesicular dysfunction, autophagy, and lipid metabolism disorders (Martinez et al., <xref ref-type="bibr" rid="B99">2017</xref>; Ma et al., <xref ref-type="bibr" rid="B95">2018</xref>; Gaeta et al., <xref ref-type="bibr" rid="B56">2019</xref>). The severity of dopaminergic dysfunction depends on the number of copies of the introduced transgene, the features of its structure (wild-type <italic>SNCA</italic> transgene or missense mutations that cause PD), and the promoters used (their tissue specificity and potency). Several <italic>C. elegans</italic> genes have also been described that affect the cytotoxicity of transgenic synuclein and are associated with endocytosis (Lakso et al., <xref ref-type="bibr" rid="B81">2003</xref>; Kuwahara et al., <xref ref-type="bibr" rid="B80">2006</xref>; Gaeta et al., <xref ref-type="bibr" rid="B56">2019</xref>). <italic>VPS41</italic>, which is expressed at a high level in dopaminergic neurons, is among the genes that were identified by siRNA screening. This gene encodes a protein involved in transport between the Golgi complex and lysosomes. As previously shown, its overexpression protects SH-SY5Y neuronal cells from the toxic effects of 6-hydroxydopamine and rotenone (Ruan et al., <xref ref-type="bibr" rid="B134">2010</xref>). This indicates the possibility of using the <italic>C. elegans</italic> model not only for the analysis of known causative genes for PD but also for the search for new candidate genes for the disease.</p>
<p>An ortholog of gene <italic>LRRK2</italic> gene, <italic>Lrk-1</italic>, was found in the <italic>C. elegans</italic> genome. This gene is actively expressed in nematode nerve cells. Knockout of this gene does not lead to the death of dopaminergic neurons and pronounced motor impairments. On the contrary, a decrease in the level of dopamine with pronounced motor abnormalities is observed in transgenic animals carrying the human <italic>LRRK2</italic> gene with pathogenetically significant missense mutations. In this case, the death of dopaminergic neurons may be associated with a violation of both the kinase and GTPase activity of the LRRK2 protein (Seegobin et al., <xref ref-type="bibr" rid="B140">2020</xref>). On the other hand, expression of the wild-type human <italic>LRRK2</italic> gene increases the resistance of the nematode to the toxic effects of rotenone and paraquat. These data indicate the importance of this kinase for the normal functioning of the organism (Langston et al., <xref ref-type="bibr" rid="B82">2016</xref>). It would be extremely important to further study the role of LRRK2 protein in the <italic>C. elegans</italic> model using other pathogenic mutations.</p>
<p>In addition to genetic ones, toxic models of PD are widely generated using <italic>C. elegans</italic>. A large number of toxins have been identified that cause degeneration of dopaminergic neurons. The most actively studied toxins are 6-hydroxydopamine, MPTP, paraquat, and rotenone; however, several other compounds are toxic to dopaminergic neurons (for example, manganese ion and several pesticides; Jadiya and Nazir, <xref ref-type="bibr" rid="B71">2012</xref>). In some cases, genetically modified nematode lines are required for the determination of toxic effects. Thus, 6-hydroxydopamine is active only in nematode lines expressing the dopamine transporter gene, which is necessary for the entry of the toxin into dopaminergic neurons (Nass et al., <xref ref-type="bibr" rid="B113">2002</xref>). All of these toxins cause a decrease in the level of ATP in cells as a result of the development of mitochondrial dysfunction; in turn, damage to mitochondrial DNA replication can play an important role in the development of this condition (Zhou et al., <xref ref-type="bibr" rid="B180">2013</xref>). In addition, toxins activate apoptotic processes and disrupt the folding of antioxidant proteins (Lehtonen et al., <xref ref-type="bibr" rid="B85">2016</xref>; Offenburger et al., <xref ref-type="bibr" rid="B117">2018</xref>).</p>
<p>Furthermore, <italic>C. elegans</italic> can be used to search for new toxins that cause degeneration of dopaminergic neurons. An analysis performed using <italic>C. elegans</italic> revealed the toxic effect of the heterocyclic amine beta-carboline, which is found in fried meat, roasted coffee, and tobacco (Sammi et al., <xref ref-type="bibr" rid="B136">2018</xref>).</p>
<p>Several interesting results have been gathered from the study of the interaction between external factors and the orthologs of genes of monogenic forms of PD. This type of Gene &#x000D7; Environment (G&#x000D7;E) analysis not only affords a better understanding of the mechanisms of toxicity of various compounds but also allows the identification of natural and synthetic neuroprotectors that block, at least partially, the negative effects of the genetic damage associated with PD (Martinez et al., <xref ref-type="bibr" rid="B99">2017</xref>; Garcia-Moreno et al., <xref ref-type="bibr" rid="B58">2019</xref>).</p>
<p>The nematode can also be used to confirm the biological activity of small macromolecules identified by screening using other biological systems, such as yeast cells. For example, the analysis of yeast cells expressing transgenic alpha-synuclein led to the identification of <italic>N</italic>-aryl benzimidazole (NAB), which blocks the toxicity of alpha-synuclein through the activation of E3 ubiquitin ligase Rsp/Nedd4. The same activity was found for NAB in a nematode model overexpressing mutant alpha-synuclein. Moreover, NAB normalizes vesicular transport both in yeast and the nematode (Tardiff et al., <xref ref-type="bibr" rid="B153">2013</xref>).</p>
<p><italic>C. elegans</italic> modeling can be used to study the role of the microbiome in the development of PD. It was shown that metabolites of the soil bacterium <italic>S. venezuelae</italic> isolated from the culture medium cause several pathological disorders in the nematode that are characteristic of sporadic PD. In particular, mitochondrial dysfunction, impaired functioning of the proteasome system, and mitophagy processes were identified. Concomitantly, in the course of the development of the pathological process, there was a transition from a violation of individual metabolic processes to complex generalized disorders (such as mitophagy). Metabolites of other types of bacteria, including those that are characteristic of the human microbiome, can have a similar effect. Consequently, the nematode represents a convenient object for the search and detailed characterization of such metabolites (Caldwell et al., <xref ref-type="bibr" rid="B23">2018</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>Step Forward: Vertebrates, from Simple to Complex</title>
<sec id="s4-1">
<title>Fish Models: Zebrafish and Medaka</title>
<p>Zebrafish (<italic>Danio rerio</italic>) and medaka (<italic>Oryzias latipes</italic>) are two fish species that are characterized by small size, rapid attainment of sexual maturity, relatively simple maintenance and reproduction, and the possibility of detailed analysis of motor behavior disorders (Orger and de Polavieja, <xref ref-type="bibr" rid="B119">2017</xref>; Vaz et al., <xref ref-type="bibr" rid="B157">2018</xref>). It should be noted that an overwhelming amount of work has been carried out using the zebrafish model, while practically only one laboratory works with medaka (Matsui et al., <xref ref-type="bibr" rid="B101">2012</xref>, <xref ref-type="bibr" rid="B104">2014</xref>; Matsui and Takahashi, <xref ref-type="bibr" rid="B100">2018</xref>).</p>
<p>As vertebrates, fish are much closer to humans regarding the genomic organization and physiological characteristics than nematodes and <italic>Drosophila</italic>. The brain of these fish species consists of three sections (forebrain, midbrain, and hindbrain) and is separated from the remainder of the body by the blood-brain barrier. In the brains of these fishes, dopaminergic neurons were found in the posterior tuberculum, which can be considered as an analog of the substantia nigra from mammals. Genetically, zebrafish and medaka are closer to humans than are fruit flies and nematodes; for example, 70% of human genes have orthologs in the zebrafish genome, including orthologs of genes that cause the familial forms of PD (<italic>LRRK2</italic>, <italic>PRKN</italic>, <italic>DJ1</italic>, and <italic>PINK1</italic>). However, similar to <italic>Drosophila</italic> and nematodes, the zebrafish genome does not possess an ortholog of the alpha-synuclein gene, although it carries orthologs of other synuclein genes: those encoding &#x003B2;-, &#x003B3;1-, and &#x003B3;2-synuclein (Howe D. G. et al., <xref ref-type="bibr" rid="B66">2013</xref>). Collections of <italic>D. rerio</italic> lines with various mutations have been created, which facilitate their use for research purposes; moreover, a database on this fish species is available<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref> (Howe K. et al., <xref ref-type="bibr" rid="B67">2013</xref>). Methods for generating various mutations in the <italic>D. rerio</italic> genome have been developed. In addition, the technology based on morpholino antisense oligonucleotides is widely used because it allows the simple and quick generation of a knockout model of any gene and the tracing of the effect of this knockout on the development of an organism, starting at the one-cell stage.</p>
<p>For example, knockout of the &#x003B2;- and &#x003B3;1-synuclein genes in zebrafish leads to motor impairment against the background of impaired development of dopaminergic neurons and a decrease in dopamine levels (Milanese et al., <xref ref-type="bibr" rid="B110">2012</xref>). A similar phenotype is observed upon overexpression of &#x003B3;1-synuclein. However, the most pronounced disturbances in the dopaminergic system are observed after overexpression of the human <italic>SNCA</italic> transgene in zebrafish (Prabhudesai et al., <xref ref-type="bibr" rid="B130">2012</xref>), and these disorders are associated with dysfunction of the ubiquitin proteasome system. Thus, the <italic>D. rerio</italic> model can be used to analyze the complex relationships between the different forms of synucleins during the process of dopaminergic neuron death. In addition, a <italic>D. rerio</italic> model was used to analyze the molecular mechanisms of neurodegeneration associated with other genes responsible for monogenic forms of PD (such as <italic>LRRK2</italic>, <italic>PINK1</italic>, <italic>ATP13A2</italic>, and <italic>PRKN</italic>; Matsui et al., <xref ref-type="bibr" rid="B102">2013a</xref>,<xref ref-type="bibr" rid="B103">b</xref>) and to search for genes associated with neuroprotection (Pinho et al., <xref ref-type="bibr" rid="B125">2016</xref>; Hu et al., <xref ref-type="bibr" rid="B68">2017</xref>; Feng et al., <xref ref-type="bibr" rid="B48">2019</xref>). However, the results obtained in different studies may not coincide. Conflicting data were obtained using morpholine knockout and knockdown of the orthologous <italic>LRRK2</italic> gene. Depending on the dose of morpholine and the target domain in the LRRK2 protein molecule, both complete embryonic lethality and partial dopaminergic neuron dysfunction with the formation of inclusions of beta-synuclein in different types of neurons could be observed (Prabhudesai et al., <xref ref-type="bibr" rid="B129">2016</xref>). Transgenic <italic>D. rerio</italic> carrying the wild-type human <italic>LRRK2</italic> gene exhibit increased locomotor activity, while the G2019S mutation disrupted the functioning of the ubiquitin-proteasome system in transgenic <italic>D. rerio</italic> (Seegobin et al., <xref ref-type="bibr" rid="B140">2020</xref>). However, as in the case of the nematode, it is necessary to obtain and analyze a larger number of transgenic lines of zebrafish with various pathogenetically significant mutations.</p>
<p>In addition to genetic modifications, zebrafish are susceptible to various toxins that cause the selective death of dopaminergic neurons, such as the well-known MPTP, 6-hydroxydopamine, and rotenone (Sarath Babu et al., <xref ref-type="bibr" rid="B138">2016</xref>; Wang et al., <xref ref-type="bibr" rid="B166">2017</xref>; Zhang et al., <xref ref-type="bibr" rid="B179">2017</xref>; Zeng et al., <xref ref-type="bibr" rid="B178">2018</xref>). The effects of toxins vary depending on the scheme of drug administration (intraperitoneal administration or injecting a toxin into the water) and the stage of ontogenesis. This must be considered when modeling a pathological process and comparing the results obtained in different experiments.</p>
<p>The zebrafish model can be used to assess the potential neurotoxicity of normal metabolites, new pesticides, and other newly synthesized chemical compounds (Li et al., <xref ref-type="bibr" rid="B87">2014</xref>; Lulla et al., <xref ref-type="bibr" rid="B94">2016</xref>; Ren et al., <xref ref-type="bibr" rid="B132">2016</xref>) as well as for the rapid screening of compounds with suspected neuroprotective activity. For example, the neurotoxicity of dopaminaldehyde (DOPAL), which is one of the metabolites of dopamine and L-DOPA, has been shown. These data draw attention to the question of the role of endogenous metabolites in the induction of neurodegenerative processes and indicate the importance of the selection of adequate therapeutic concentrations of L-DOPA, to prevent the formation of excessive amounts of DOPAL (Stednitz et al., <xref ref-type="bibr" rid="B148">2015</xref>).</p>
<p>Conversely, zebrafish models, both toxic and genetic, have been used to screen for compounds with neuroprotective activity (Feng et al., <xref ref-type="bibr" rid="B49">2016</xref>, <xref ref-type="bibr" rid="B48">2019</xref>; Cronin and Grealy, <xref ref-type="bibr" rid="B33">2017</xref>; Li et al., <xref ref-type="bibr" rid="B86">2018</xref>; Soman et al., <xref ref-type="bibr" rid="B145">2019</xref>; Wang et al., <xref ref-type="bibr" rid="B163">2019</xref>; &#x000DC;nal et al., <xref ref-type="bibr" rid="B156">2020</xref>). Several protocols have been proposed for the rapid screening of such compounds (Pitchai et al., <xref ref-type="bibr" rid="B126">2019</xref>). In addition, fundamentally new potential mechanisms for the prevention of neurodegeneration in PD have been identified; for example, the blockage of the expression of the histone deacetylase (HDAC) HDAC1 and HDAC6 (Pinho et al., <xref ref-type="bibr" rid="B125">2016</xref>).</p>
</sec>
<sec id="s4-2">
<title>Modeling on Mammals: Minipigs and Others</title>
<p>As mentioned above, an overwhelming amount of work aimed at modeling PD has been carried out in mammals, especially using mice and rats. The role of these rodent species is especially prominent in the toxic modeling of the disease because more than 95% of all such experiments have been performed using these models. Moreover, regarding genetic modeling, rodents occupy an honorable first place, as at least 80% of all work has been carried out using mice and rats (Kin et al., <xref ref-type="bibr" rid="B76">2019</xref>). Nevertheless, PD modeling work has also been performed using other types of mammals, such as minipigs, dogs, and various species of primates.</p>
<p>The first report of PD modeling in G&#x000F6;ttingen minipigs was published in 1999 (Mikkelsen et al., <xref ref-type="bibr" rid="B109">1999</xref>). Moreover, it was shown that, in these animals, MPTP causes a decrease in the level of dopamine and the death of dopaminergic neurons in the substantia nigra, which leads to impaired motor behavior. Several different protocols of toxin administration have been proposed, and a micropump-based chronic continuous MPTP administration method has been developed that provides stable disruption of dopamine metabolism and behavior when administered at 12&#x02013;18 mg of the drug per day for 11 weeks (Nielsen et al., <xref ref-type="bibr" rid="B115">2016</xref>).</p>
<p>It is necessary to emphasize the high similarity of the brain structure between humans and minipigs, as well as the large size of the substantia nigra and striatum in minipigs. This facilitates the comprehensive molecular biological and biochemical analyses that are necessary for PD modeling (Wakeman et al., <xref ref-type="bibr" rid="B162">2006</xref>; Nielsen et al., <xref ref-type="bibr" rid="B116">2009</xref>). Their large brain size also allows the effective use of positron emission tomography analysis of brain structures, to monitor the development of neurodegeneration and changes in the nervous system, to correct neurodegenerative changes (e.g., the transplantation of embryonic mesencephalic neurons into animals with MPTP-induced parkinsonism; Danielsen et al., <xref ref-type="bibr" rid="B36">2000</xref>). Large brain size also increases the ability to perform stereotaxic operations, for example, to obtain a 6-hydroxydopamine model of PD (Christensen et al., <xref ref-type="bibr" rid="B29">2018</xref>). It has been shown that unilateral injection of the toxin into the nigrostriatal pathway induces a characteristic rotational behavior in minipigs, which is induced by the administration of amphetamine or deep brain stimulation on the affected side. Other toxic models of PD in minipigs have also been proposed, including a model based on the introduction of the proteasome inhibitor lactacystin into the medial forebrain bundle (Lillethorup et al., <xref ref-type="bibr" rid="B89">2018</xref>).</p>
<p>Genetic models of PD were also obtained using Guangxi Bama minipigs based on the introduction of a human <italic>SNCA</italic> transgene carrying pathogenetically significant missense mutations (Zhu et al., <xref ref-type="bibr" rid="B181">2018</xref>) or heterozygous knockout of three PD genes simultaneously (<italic>PINK1</italic>/<italic>DJ-1</italic>/<italic>PRKN</italic>, Wang et al., <xref ref-type="bibr" rid="B165">2016</xref>). However, in both cases, transgenic minipigs did not exhibit any of the motor disorders that are typical of PD at the age of 3 and 10 months. Moreover, no PD-specific histopathological changes were detected in the substantia nigra and striatum. These findings may be attributed to the slow development of the pathological process in transgenic animals.</p>
<p>An extremely important area of research using minipigs is the analysis of new therapeutic approaches for PD because the great similarity of the anatomy and physiology between minipigs and humans allows a more accurate assessment of the relevance of the proposed treatment methods (Sousa e Silva et al., <xref ref-type="bibr" rid="B147">2011</xref>; Lin et al., <xref ref-type="bibr" rid="B90">2013</xref>; Ramot et al., <xref ref-type="bibr" rid="B131">2017</xref>; Kahana et al., <xref ref-type="bibr" rid="B75">2020</xref>).</p>
<p>Dogs, in which mutations in genes responsible for monogenic forms of PD have been described, may represent a promising research direction in the field of PD modeling.</p>
<p>For example, a mutation in the <italic>ATP13A2</italic> (PARK9) gene has been described in the Tibetan terrier, which results in the formation of a truncated protein variant. In the homozygous form, this mutation leads to the development of adult-onset neuronal ceroid-lipofuscinosis, the phenotype of which partially overlaps with the PARK9 phenotype of PD (Farias et al., <xref ref-type="bibr" rid="B46">2011</xref>). It would be extremely interesting to develop such a PD phenotype in terriers heterozygous for this mutation. Other mutations have been reported in dogs that cause dysfunction of the brain regions associated with Parkinson&#x02019;s disease. For example, the development of multiple systemic atrophy in the Chinese crested dog and Kerry blue terrier, which affects the substantia nigra, is associated with the genomic region in which the <italic>parkin</italic> gene is located in dogs (W&#x000F6;hlke et al., <xref ref-type="bibr" rid="B171">2011</xref>).</p>
<p>However, most importantly, dogs may be used in future research to study the role of the microbiome and the interaction between the brain and the gastrointestinal tract in the development of neurodegenerative diseases and, in particular, PD (Ambrosini et al., <xref ref-type="bibr" rid="B2">2019</xref>). Dogs allow the study of the brain&#x02014;gastrointestinal tract axis both <italic>in vitro</italic> (organoid cultures of the intestine, various variants of model constructs based on microfluidic technologies) and <italic>in vivo</italic>, especially given the relatively similar nature of nutrition between humans and dogs.</p>
<p>Nonhuman primates allow disease modeling in species more closely related to humans. Despite the obvious drawback of the high cost of work using primates, interest in these models has grown in recent years, primarily because primates can be used to develop new treatments for PD associated with the use of deep brain stimulation and transplantation of neuronal cells into the substantia nigra and striatum, as well as for testing newly developed drugs in the final stages of preclinical research (Fiandaca and Bankiewicz, <xref ref-type="bibr" rid="B50">2010</xref>; Sundberg et al., <xref ref-type="bibr" rid="B151">2013</xref>; Faggiani and Benazzouz, <xref ref-type="bibr" rid="B44">2017</xref>; Wianny and Vezoli, <xref ref-type="bibr" rid="B167">2017</xref>; Morissette and Di Paolo, <xref ref-type="bibr" rid="B111">2018</xref>; Pignataro et al., <xref ref-type="bibr" rid="B124">2018</xref>; Wichmann et al., <xref ref-type="bibr" rid="B168">2018</xref>; Deffains and Bergman, <xref ref-type="bibr" rid="B38">2019</xref>; Rosenblad et al., <xref ref-type="bibr" rid="B133">2019</xref>; Teil et al., <xref ref-type="bibr" rid="B154">2020</xref>). Moreover, the similarity of the organization of the nervous systems of humans and primates is fundamentally important because it allows the assessment in greater detail of the involvement of different brain structures in the development of the pathological process of PD, to analyze the temporal dynamics of this disorder (Verhave et al., <xref ref-type="bibr" rid="B159">2011</xref>; Fifel et al., <xref ref-type="bibr" rid="B51">2014</xref>; Vezoli et al., <xref ref-type="bibr" rid="B160">2014</xref>; Ko et al., <xref ref-type="bibr" rid="B77">2018</xref>; Sgambato and Tremblay, <xref ref-type="bibr" rid="B142">2018</xref>; Wang et al., <xref ref-type="bibr" rid="B164">2018</xref>; Deffains and Bergman, <xref ref-type="bibr" rid="B38">2019</xref>; McGregor and Nelson, <xref ref-type="bibr" rid="B106">2019</xref>). Nonhuman primate models also permit the simulation of the early, premotor, stage of PD; for example, sleep disorders (Bezard and Fernagut, <xref ref-type="bibr" rid="B10">2014</xref>).</p>
<p>Previously, the injection of the MPTP toxin into primates was widely used in disease modeling (Fifel et al., <xref ref-type="bibr" rid="B51">2014</xref>; Johnston and Fox, <xref ref-type="bibr" rid="B74">2015</xref>; Rosenblad et al., <xref ref-type="bibr" rid="B133">2019</xref>), to simulate the acute and chronic development of the pathological process in various nonhuman primates. Moreover, the exact dosage of the toxin to be administered to each animal is extremely important, with the possibility of correcting the amount of toxin injected according to the comprehensive assessment of the behavior of animals during the modeling process (Seo et al., <xref ref-type="bibr" rid="B141">2019</xref>).</p>
<p>In recent years, a new direction of the work on the modeling of PD in primates is being actively developed in association with the use of alpha-synuclein as a toxin. In this context, various options for the introduction of alpha-synuclein were used. Koprich et al. (<xref ref-type="bibr" rid="B78">2016</xref>) injected the protein into the substantia nigra of cynomolgus macaques using the adeno-associated virus 1/2 (AAV1/2) vector carrying the transgene encoding human alpha-synuclein with the A53T mutation, thereby causing a decrease in the level of dopamine in the striatum and the death of dopaminergic neurons. It was later shown that the death of dopaminergic neurons with the formation of inclusions similar to Lewy bodies in TH-positive neurons can be caused in the common marmoset via the introduction of synthetic fibrillar alpha-synuclein into the region of the caudate nucleus or putamen (Shimozawa et al., <xref ref-type="bibr" rid="B143">2017</xref>). Furthermore, the spread of the injected alpha-synuclein was observed in the brain, where it behaved as a prion-like protein. This spread was also observed after the introduction of alpha-synuclein (both as a fibrillar protein and a transgene in the AAV vector) into the neural plexuses of the intestinal submucosa. Alpha-synuclein inclusions were detected in the dorsal motor nucleus and locus coeruleus but were not accompanied by any symptoms of PD (except for intestinal dysfunction associated with damage to submucosal neurons; Manfredsson et al., <xref ref-type="bibr" rid="B98">2018</xref>). Apparently, the results of the administration of alpha-synuclein depend greatly on the form in which it is administered, i.e., as a monomeric protein (in phosphorylated or dephosphorylated form) or as preformed fibrils (G&#x000F3;mez-Benito et al., <xref ref-type="bibr" rid="B60">2020</xref>). The formation of Lewy bodies and neurites and interneuronal transmission of the introduced aggregates are observed only in the latter case. This indicates the importance of the onset of fibrillogenesis in the development of PD and the need to develop therapies aimed at blocking the formation of fibrillar alpha-synuclein or the interneuronal transmission of preformed fibrils (Hijaz and Volpicelli-Daley, <xref ref-type="bibr" rid="B64">2020</xref>; Teil et al., <xref ref-type="bibr" rid="B154">2020</xref>). In addition, the results of the introduction of different variants of alpha-synuclein isolated from the brains of deceased patients with PD into nonhuman primates show a complex picture for the development of neuronal disorders involving various brain structures. However, ultimately, nonhuman primates develop dopaminergic neuron degeneration (Bourdenx et al., <xref ref-type="bibr" rid="B14">2020</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion" id="s5">
<title>Discussion</title>
<p>At present, a very large arsenal of models has been developed to study various aspects of the etiopathogenesis of PD <italic>in vivo</italic> using various model organisms, from unicellular eukaryotes to nonhuman primates. In this context, it is extremely important to select the optimal biological model for solving a specific problem.</p>
<p>We have summarized the main characteristics of all the models described above in <xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="fig" rid="F1">Figure 1</xref>. It is obvious that each of the models has its own set of advantages and disadvantages that must be taken into account when choosing a model system for solving a specific problem. For example, the analysis of the individual stages of biological processes that are associated with the development of a disease (for example, autophagy or mitochondrial biogenesis) can be carried out using the simplest models, such as yeast, nematode, or <italic>Drosophila</italic>. In this case, new biological patterns can be revealed and key proteins that control specific biological processes can be identified. Such models are relatively simple from the point of view of the possibility of manipulating their genomes and creating complex genetic models, including the introduction into their genomes of mutant genes associated with the development of a pathological process in humans. Conversely, these simple models are genetically very distant from humans and their genomes may not contain the genes that are critical for the development of PD. A striking example is the genes encoding the proteins of the synuclein family, primarily the alpha-synuclein gene, which is absent in the genomes of all of the simpler model organisms. Because of this genetic remoteness, individual biological processes may proceed differently in model objects and in humans, and it is necessary to confirm the patterns identified in these objects using more complex models. It should also be noted that these models either do not have a nervous system (yeast) or have a nervous system that is very distantly related to the nervous system of primates and humans. Both <italic>Drosophila</italic> and nematodes have dopaminergic neurons, and their dysfunction can be actively studied in these models; however, the organization of neural networks with the participation of neurons of this type is fundamentally different both between these two models and between these models and primates.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption><p>Brief characteristics, advantages, and disadvantages of the model objects.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center">Yeast</th>
<th align="center">Fruit fly</th>
<th align="center">Nematode</th>
<th align="center">Zebrafish</th>
<th align="center">Minipigs</th>
<th align="center">Dogs</th>
<th align="center">Nonhuman primates</th>
</tr>
<tr>
<td align="center" colspan="8">General characteristics of the model object</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Taxonomy</td>
<td align="left">Unicellular fungi</td>
<td align="left">Invertebrates, insects</td>
<td align="left">Invertebrates, roundworms</td>
<td align="left">Vertebrates, fish</td>
<td align="left">Vertebrates, mammals</td>
<td align="left">Vertebrates, mammals</td>
<td align="left">Vertebrates, mammals</td>
</tr>
<tr>
<td align="left">Life span</td>
<td align="left">From several days to 2 weeks</td>
<td align="left">About 2 month</td>
<td align="center">15&#x02013;25 days</td>
<td align="left">Max. 2 years.</td>
<td align="center">10&#x02013;15 years</td>
<td align="center">10&#x02013;13 years</td>
<td align="center">5&#x02013;40 years for different species</td>
</tr>
<tr>
<td align="left">The presence and complexity of the nervous system</td>
<td align="left">Absent</td>
<td align="left">The presence of various types of glial and neuronal cells (including dopaminergic), a blood&#x02013;brain barrier, motor neurons, and interneurons</td>
<td align="left">The presence of 302 nerve cells, which have been characterized in detail regarding their function and synaptic contacts using dopamine, serotonin, glutamate, acetylcholine, and GABA as neurotransmitters</td>
<td align="left">The brain consists of three sections (forebrain, midbrain, and hindbrain) and is separated from the remainder of the body by the blood&#x02013;brain barrier. Dopaminergic neurons were found in the posterior tuberculum, which can be considered as an analog of the substantia nigra in mammals.</td>
<td align="left">The high similarity of the brain structure between humans and minipigs, as well as the large size of the substantia nigra and striatum in minipigs</td>
<td align="left">The high similarity of the brain structure between humans and dogs, as well as the large size of the substantia nigra and striatum</td>
<td align="left">The high similarity of the brain structure between humans and primates, as well as the large size of the substantia nigra and striatum</td>
</tr>
<tr>
<td align="left">Possibility to study motor behavior</td>
<td align="left">Absent</td>
<td align="left">Climbing activity, pattern of movement, spontaneous locomotor activity</td>
<td align="left">The analysis of worm mobility after starvation: &#x0201C;basal slowing response&#x0201D; and &#x0201C;enhanced slowing response&#x0201D;, Chemotaxis, area-restricted search behavior, swim-to-crawl transition, Dauer-dependent behavior, mechanosensory responses, fecundity, and rate of defecation.</td>
<td align="left">Deficits in evoked swimming response (bradykinesia) Decrease in total distance moved and swimming velocity (bradykinesia) Increase in number and duration of freezing episodes (dyskinesia).</td>
<td align="left">Analysis of motor behavior: walking test, Hurdle test, open field locomotor activity</td>
<td align="left">Locomotor activity in open field, walking test.</td>
<td align="left">Parkinson&#x02019;s disease rating scale (PRDS) for primates.</td>
</tr>
<tr>
<td align="left">Simplicity and cost</td>
<td align="left">&#x0002B; (The most simple and inexpensive)</td>
<td align="left">&#x0002B; &#x0002B;</td>
<td align="left">&#x0002B; &#x0002B;</td>
<td align="left">&#x0002B; &#x0002B; &#x0002B; &#x0002B;</td>
<td align="left">&#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B;</td>
<td align="left">&#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B;</td>
<td align="left">&#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B; &#x0002B; (The most difficult and expensive)</td>
</tr>
<tr>
<td align="center" colspan="8"><bold>Genetic models</bold></td>
</tr>
<tr>
<td align="left">Genome sequencing and annotation</td>
<td align="left">YES</td>
<td align="left">YES</td>
<td align="left">YES</td>
<td align="left">YES</td>
<td align="left">YES</td>
<td align="left">YES</td>
<td align="left">YES</td>
</tr>
<tr>
<td align="left">Similarity to the human genome</td>
<td align="left">LOW</td>
<td align="left">LOW</td>
<td align="left">LOW</td>
<td align="left">LIMITED</td>
<td align="left">HIGH</td>
<td align="left">HIGH</td>
<td align="left">HIGH</td>
</tr>
<tr>
<td align="left">Existence of genetic models</td>
<td align="left">Exists</td>
<td align="left">Exists</td>
<td align="left">Exists</td>
<td align="left">Exists</td>
<td align="left">Exists, but not widespread</td>
<td align="left">A natural mutation in <italic>ATP13A2</italic> gene</td>
<td align="left">NO</td>
</tr>
<tr>
<td align="left">The main genes studied, homologous to human</td>
<td align="left"><italic>SNCA, LRRK2, PRKN, PINK1, PARK7, VPS35, EIF4G1, ATP13A2</italic></td>
<td align="left"><italic>SNCA, LRRK2, PRKN, PINK1, PARK7, VPS35, GBA</italic></td>
<td align="left"><italic>SNCA, LRRK2, PINK1, PRKN, PARK7, ATP13A2</italic></td>
<td align="left"><italic>SNCA, LRRK2, PRKN, PINK1, ATP13A2</italic></td>
<td align="left"><italic>SNCA, PINK1/ PARK7/PRKN</italic></td>
<td align="left"><italic>ATP13A2</italic></td>
<td align="left">NO</td>
</tr>
<tr>
<td align="left">Methods</td>
<td align="left">knockout, knockdown, and overexpression, transgenic (mutant) animals</td>
<td align="left">knockout, knockdown, and overexpression, transgenic (mutant) animals</td>
<td align="left">knockout, knockdown, and overexpression, transgenic (mutant) animals</td>
<td align="left">knockout, knockdown, and overexpression, transgenic (mutant) animals; the technology based on morpholino antisense oligonucleotides.</td>
<td align="left">knockout, transgenic (mutant) animals</td>
<td align="left">A natural mutation</td>
<td align="left">NO</td>
</tr>
<tr>
<td align="left">Collection of mutant lines of animals</td>
<td align="left">Yeast Insertional Mutant Collection</td>
<td align="left">The presence of a large collection of fruit fly lines with various mutations.</td>
<td align="left">The presence of a large collection of mutant nematode lines</td>
<td align="left">The presence of collections of <italic>D. rerio</italic> lines with various mutations</td>
<td align="left">Absent</td>
<td align="left">Absent</td>
<td align="left">Absent</td>
</tr>
<tr>
<td align="left">Application area</td>
<td align="left">Analysis of selected genes / proteins associated with the development of the disease. Primary screening for new drugs.</td>
<td align="left">Analysis of selected genes / proteins associated with the development of the disease</td>
<td align="left">Analysis of molecular mechanisms of neurodegeneration associated with genes of monogenic forms of Parkinson&#x02019;s disease</td>
<td align="left">Analysis of molecular mechanisms of neurodegeneration associated with genes of monogenic forms of Parkinson&#x02019;s disease; search for genes associated with neuroprotection</td>
<td align="left">Comprehensive molecular biological and biochemical analysis; positron emission tomography analysis of brain structures, to monitor the development of neurodegeneration and changes in the nervous system, to correct neurodegenerative changes</td>
<td align="left">Comprehensive molecular biological and biochemical analysis; a study of possible microbiome involvement in neurodegeneration</td>
<td align="left">NO</td>
</tr>
<tr>
<td align="center" colspan="8"><bold>Toxicity models</bold></td>
</tr>
<tr>
<td align="left">Existence</td>
<td align="left">NO</td>
<td align="left">Exists, but not widespread</td>
<td align="left">Exists</td>
<td align="left">Exists</td>
<td align="left">Exists</td>
<td align="left">NO</td>
<td align="left">Exists</td>
</tr>
<tr>
<td align="left">Toxins</td>
<td align="left">NO</td>
<td align="left">The rotenone and MPTP</td>
<td align="left">6-hydroxydopamine, MPTP, paraquat, and rotenone</td>
<td align="left">6-hydroxydopamine, MPTP, paraquat, and rotenone</td>
<td align="left">6-hydroxydopamine, MPTP</td>
<td align="left">NO</td>
<td align="left">MPTP<italic>SNCA</italic></td>
</tr>
<tr>
<td align="left">Methods</td>
<td align="left">NO</td>
<td align="left">Addition of a toxin into the food</td>
<td align="left">Addition of a toxin into the food</td>
<td align="left">Intraperitoneal administration or addition of a toxin into the water</td>
<td align="left">Unilateral injection of the toxin into the nigrostriatal pathway, a micropump-based chronic continuous MPTP administration</td>
<td align="left">NO</td>
<td align="left">Acute and chronic MPTP administration. <italic>SNCA</italic> as pure fibrillar protein or AV-based expression cassette</td>
</tr>
<tr>
<td align="left">Application area</td>
<td align="left">NO</td>
<td align="left">Toxic models in the future can be used to search for new antiparkinsonian drugs</td>
<td align="left">Search for new toxins that damage dopaminergic neurons; Analysis of biologically active substances; Study of microbiome</td>
<td align="left">Screening for compounds with neuroprotective activity; Assessment of the potential neurotoxicity of normal metabolites, new pesticides, and other newly synthesized chemical compounds</td>
<td align="left">Positron emission tomography analysis of brain structures for monitoring of the development of neurodegeneration, changes in the nervous system, and correction of neurodegenerative changes; the analysis of new therapeutic approaches for PD</td>
<td align="left">NO</td>
<td align="left">Development of new treatments for Parkinson&#x02019;s disease associated with the use of deep brain stimulation, transplantation of neuronal cells into the substantia nigra and striatum, and for testing newly developed drugs in the last stages of preclinical studies</td>
</tr>
<tr>
<td align="center" colspan="8"><bold>Advantages and disadvantages</bold></td>
</tr>
<tr>
<td align="left">Advantages</td>
<td align="left">Simple system. The ability to obtain various mutations in genes associated with the development of the disease. Possibility of studying protein-protein interactions, searching for new candidate disease genes. Rapid initial screening of new potential neuroprotective drugs</td>
<td align="left">A relatively simple and well-established system. The presence of large collections of mutant lines. Possibility of using both genetic and toxic models. The presence of a well-studied nervous system. There are dopaminergic neurons. Short lifespan. Possibility to study the relationship between aging and neurodegeneration</td>
<td align="left">Ability to use a wide range of genetic and toxic models. Well-characterized nervous system, presence of neurons of different energies. Possibility of analyzing motor behavior. Short lifespan and the ability to analyze neurodegenerative changes in animals of different ages. Ease of maintenance and reproduction, low cost.</td>
<td align="left">Ability to use a wide range of genetic and toxic models. Sufficiently high homology with the human genome, there are orthologs for most of the genes associated with the development of PD. A detailed description of the nervous system, the presence of neurons of different energies. Possibility to analyze motor behavior.</td>
<td align="left">The high similarity of metabolism in general and organization of the nervous system to human analogs. Possibility of visualization of substantia nigra during PET scanning. Possibility of using toxic and genetic models. Possibility of testing antiparkinsonian drugs and other therapies.</td>
<td align="left">Natural mutations in the genes of familial forms of PD, which make it possible to study manifestations in ontogenesis.</td>
<td align="left">Possibility to analyze the clinical phenotype as close as possible to the clinical phenotype of PD in humans. Development of protocols for new methods of therapy on animals as close to humans as possible.</td>
</tr>
<tr>
<td align="left">Disadvantages</td>
<td align="left">Unicellular organism. The nervous system is completely absent. There are no orthologs for a number of genes that are fundamentally important for PD, primarily, orthologs of the synuclein gene.</td>
<td align="left">Lack of orthologs for a number of genes that are fundamentally important for PD, primarily orthologs of synuclein genes. A fundamentally different organization of the nervous system in comparison with vertebrates and humans.</td>
<td align="left">Lack of orthologs for a number of genes important for the development of PD. The ortholog of the synuclein genes is absent. There are significant differences in the organization of the nervous system from higher vertebrates.</td>
<td align="left">More difficult conditions for keeping in comparison with nematodes and fruit flies. Longer lifespan, which complicates the study of the effects of aging on neurodegeneration processes.</td>
<td align="left">Very limited range of genetic models. Relative complexity and high cost of keeping the animals. Limited opportunities to study the role of aging in the development of PD.</td>
<td align="left">A very limited range of natural mutations. Lack of genetic models with targeted modification of candidate disease genes and toxic models. Limited opportunities to study the role of aging in the development of Parkinson&#x02019;s disease.</td>
<td align="left">Toxic models only. Long duration of the experiment. Very high cost of modeling. Problems with using large samples. Limited opportunities to study the role of aging in the development of Parkinson&#x02019;s disease.</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Comparison of the main characteristics of the described models: blue box&#x02014;assessment of individual characteristics of the model (0&#x02013;10 points).</p></caption>
<graphic xlink:href="fnagi-13-695718-g0001.tif"/>
</fig>
<p>This dictates the need for a transition to more complex models with an organization of the nervous system that is closer to that of humans and that affords the ability to analyze disorders of motor behavior, which is the main clinical sign of PD. However, models generated using rodents and <italic>Danio rerio</italic> have limited capabilities to manipulate the level of expression of specific genes of interest in individual organs and tissues at different stages of ontogenesis. Therefore, when working with these models, researchers actively turn toward toxic models of the disease. This allows going beyond the genes limited to the hereditary monogenic forms of PD and the identification of fundamentally new factors of etiopathogenesis. Moreover, working with these models is relatively cheap and fast because the full simulation cycle does not exceed several weeks or (in extreme cases) months. However, these animals allow very poor modeling of the early manifestations of PD, such as disturbances in fine motor processes, sleep, and dysfunction of the gastrointestinal tract. Their analysis, which is extremely important for the development of preclinical markers of the disease, is only possible using more complex model animals, from minipigs to primates. In this regard, the models based on minipigs can be underestimated&#x02014;they are quite close to humans and allow complex experiments with various options for both genetic and toxic modeling of the disease. Of course, minipig models are inferior to primate models, but this is offset by the relatively simple maintenance and handling of minipigs at a much lower cost per animal. It is possible to use the minipig models successfully to analyze new therapeutic approaches for PD; for example, in the development of therapeutic methods based on the transplantation of neuronal cells.</p>
<p>It should be noted that the risk of developing PD increases dramatically in old age. Unfortunately, the age factor is currently poorly taken into account in disease modeling. In this regard, two model objects (<italic>Drosophila</italic> and <italic>Nematode</italic>) may be of the greatest interest. The short lifespan of these models makes it possible to assess the effect of aging on the development of neurodegenerative processes, which is extremely difficult to do in models with a long lifespan. In this case, it is always necessary to take into account the lifespan of individual lines of <italic>Drosophila</italic> and <italic>Nematodes</italic>, as well as the possible variability of this indicator within a separate line. Since the development of aging processes and the overall life expectancy are greatly influenced by environmental factors, it is necessary to strictly control the conditions of keeping model animals. This is especially important for animals with a short life cycle, where the influence of environmental factors is especially great (Cooper and Van Raamsdonk, <xref ref-type="bibr" rid="B31">2018</xref>). Even in <italic>D. rerio</italic>, the study of the aging factor requires a very long time, although in this case, maintaining a sufficiently large fish population for more than one year does not seem to be an insoluble problem. In other model vertebrates, the estimation of the age factor turns out to be practically impossible, which once again emphasizes the importance of using a wide range of different model objects and different approaches to modeling. We would like to note again that there is currently no ideal model of PD that can reflect all aspects of this disease. These aspects include &#x0201C;the age of onset, the temporal speed of the disorder, nor the spectrum of problems and pathologies you see in the clinic in patients with PD,&#x0201D; as described by Roger A. Barker in a discussion with Anders Bj&#x000F6;rklund (Barker and Bj&#x000F6;rklund, <xref ref-type="bibr" rid="B9">2020</xref>). Nevertheless, because it is impossible to study the processes occurring in nerve cells in humans <italic>in vivo</italic> at present, disease models are crucial in this field of research. We agree with Anders Bj&#x000F6;rklund, who indicated that the PD models currently available allow a more detailed study of individual mechanisms of PD pathogenesis, and can also be used for the development of new drugs and approaches for the treatment of the disease (Barker and Bj&#x000F6;rklund, <xref ref-type="bibr" rid="B9">2020</xref>). From our point of view, in this case, the development of works with the wide use of two animal models from those considered above, namely, <italic>Nematodes</italic> and <italic>D. rerio</italic>, deserves maximum attention. In both cases, these are animals with a very well-studied nervous system, the organization of which at the cellular and molecular level is close to the mammalian nervous system, which makes it possible to transfer the results obtained to humans with a sufficient degree of confidence. In both cases, a variety of variants of genetic and toxic models are possible, which makes it possible to select the optimal parameters for modeling in accordance with the set of tasks. An important advantage of the nematode is its short life cycle, which makes it possible to take into account the role of the aging factor in the development of neurodegeneration in PD.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>MS and PS reviewed the literature, discussed the concepts, and wrote the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x02019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This study was supported by Russian Science Foundation (Grant no. 20-15-00262).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abolaji</surname> <given-names>A. O.</given-names></name> <name><surname>Adedara</surname> <given-names>A. O.</given-names></name> <name><surname>Adie</surname> <given-names>M. A.</given-names></name> <name><surname>Vicente-Crespo</surname> <given-names>M.</given-names></name> <name><surname>Farombi</surname> <given-names>E. O.</given-names></name></person-group> (<year>2018</year>). <article-title>Resveratrol prolongs lifespan and improves 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced oxidative damage and behavioural deficits in <italic>Drosophila melanogaster</italic></article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>503</volume>, <fpage>1042</fpage>&#x02013;<lpage>1048</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.06.114</pub-id><pub-id pub-id-type="pmid">29935183</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini</surname> <given-names>Y. M.</given-names></name> <name><surname>Borcherding</surname> <given-names>D.</given-names></name> <name><surname>Kanthasamy</surname> <given-names>A.</given-names></name> <name><surname>Kim</surname> <given-names>H. J.</given-names></name> <name><surname>Willette</surname> <given-names>A. A.</given-names></name> <name><surname>Jergens</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>The gut-brain axis in neurodegenerative diseases and relevance of the canine model: a review</article-title>. <source>Front. Aging Neurosci.</source> <volume>11</volume>:<fpage>130</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2019.00130</pub-id><pub-id pub-id-type="pmid">31275138</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname> <given-names>M.</given-names></name> <name><surname>Funayama</surname> <given-names>M.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Kashihara</surname> <given-names>K.</given-names></name> <name><surname>Murakami</surname> <given-names>Y.</given-names></name> <name><surname>Ishizu</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>VPS35 mutation in Japanese patients with typical Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>27</volume>, <fpage>1413</fpage>&#x02013;<lpage>1417</lpage>. <pub-id pub-id-type="doi">10.1002/mds.25145</pub-id><pub-id pub-id-type="pmid">22991136</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aufschnaiter</surname> <given-names>A.</given-names></name> <name><surname>Kohler</surname> <given-names>V.</given-names></name> <name><surname>Walter</surname> <given-names>C.</given-names></name> <name><surname>Tosal-Castano</surname> <given-names>S.</given-names></name> <name><surname>Habernig</surname> <given-names>L.</given-names></name> <name><surname>Wolinski</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>The enzymatic core of the Parkinson&#x02019;s disease-associated protein LRRK2 impairs mitochondrial biogenesis in aging yeast</article-title>. <source>Front. Mol. Neurosci.</source> <volume>11</volume>:<fpage>205</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2018.00205</pub-id><pub-id pub-id-type="pmid">29977190</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auluck</surname> <given-names>P. K.</given-names></name> <name><surname>Caraveo</surname> <given-names>G.</given-names></name> <name><surname>Lindquist</surname> <given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>&#x003B1;-synuclein: membrane interactions and toxicity in Parkinson&#x02019;s disease</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source> <volume>26</volume>, <fpage>211</fpage>&#x02013;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.cellbio.042308.113313</pub-id><pub-id pub-id-type="pmid">20500090</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auluck</surname> <given-names>P. K.</given-names></name> <name><surname>Chan</surname> <given-names>H. Y.</given-names></name> <name><surname>Trojanowski</surname> <given-names>J. Q.</given-names></name> <name><surname>Lee</surname> <given-names>V. M.</given-names></name> <name><surname>Bonini</surname> <given-names>N. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Chaperone suppression of &#x003B1;-synuclein toxicity in a <italic>Drosophila</italic> model for Parkinson&#x02019;s disease</article-title>. <source>Science</source> <volume>295</volume>, <fpage>865</fpage>&#x02013;<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1126/science.1067389</pub-id><pub-id pub-id-type="pmid">11823645</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bandres-Ciga</surname> <given-names>S.</given-names></name> <name><surname>Diez-Fairen</surname> <given-names>M.</given-names></name> <name><surname>Kim</surname> <given-names>J. J.</given-names></name> <name><surname>Singleton</surname> <given-names>A. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Genetics of Parkinson&#x02019;s disease: an introspection of its journey towards precision medicine</article-title>. <source>Neurobiol. Dis.</source> <volume>137</volume>:<fpage>104782</fpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2020.104782</pub-id><pub-id pub-id-type="pmid">31991247</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bandres-Ciga</surname> <given-names>S.</given-names></name> <name><surname>Saez-Atienzar</surname> <given-names>S.</given-names></name> <name><surname>Bonet-Ponce</surname> <given-names>L.</given-names></name> <name><surname>Billingsley</surname> <given-names>K.</given-names></name> <name><surname>Vitale</surname> <given-names>D.</given-names></name> <name><surname>Blauwendraat</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>34</volume>, <fpage>460</fpage>&#x02013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1002/mds.27614</pub-id><pub-id pub-id-type="pmid">30675927</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname> <given-names>R. A.</given-names></name> <name><surname>Bj&#x000F6;rklund</surname> <given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Animal models of Parkinson&#x02019;s disease: are they useful or not?</article-title> <source>J. Parkinsons Dis.</source> <volume>10</volume>, <fpage>1335</fpage>&#x02013;<lpage>1342</lpage>. <pub-id pub-id-type="doi">10.3233/JPD-202200</pub-id><pub-id pub-id-type="pmid">32716322</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bezard</surname> <given-names>E.</given-names></name> <name><surname>Fernagut</surname> <given-names>P.-O.</given-names></name></person-group> (<year>2014</year>). <article-title>Premotor parkinsonism models</article-title>. <source>Parkinsonism Relat. Disord.</source> <volume>20</volume>, <fpage>S17</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/S1353-8020(13)70007-5</pub-id><pub-id pub-id-type="pmid">24262174</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bilen</surname> <given-names>J.</given-names></name> <name><surname>Bonini</surname> <given-names>N. M.</given-names></name></person-group> (<year>2005</year>). <article-title><italic>Drosophila</italic> as a model for human neurodegenerative disease</article-title>. <source>Annu. Rev. Genet.</source> <volume>39</volume>, <fpage>153</fpage>&#x02013;<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.genet.39.110304.095804</pub-id><pub-id pub-id-type="pmid">16285856</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Billingsley</surname> <given-names>K. J.</given-names></name> <name><surname>Bandres-Ciga</surname> <given-names>S.</given-names></name> <name><surname>Saez-Atienzar</surname> <given-names>S.</given-names></name> <name><surname>Singleton</surname> <given-names>A. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Genetic risk factors in Parkinson&#x02019;s disease</article-title>. <source>Cell Tissue Res.</source> <volume>373</volume>, <fpage>9</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-018-2817-y</pub-id><pub-id pub-id-type="pmid">29536161</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Billingsley</surname> <given-names>K. J.</given-names></name> <name><surname>Barbosa</surname> <given-names>I. A.</given-names></name> <name><surname>Bandres-Ciga</surname> <given-names>S.</given-names></name> <name><surname>Quinn</surname> <given-names>J. P.</given-names></name> <name><surname>Bubb</surname> <given-names>V. J.</given-names></name> <name><surname>Deshpande</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Mitochondria function associated genes contribute to Parkinson&#x02019;s disease risk and later age at onset</article-title>. <source>NPJ Parkinsons Dis.</source> <volume>5</volume>:<fpage>8</fpage>. <pub-id pub-id-type="doi">10.1038/s41531-019-0080-x</pub-id><pub-id pub-id-type="pmid">31123700</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bourdenx</surname> <given-names>M.</given-names></name> <name><surname>Nioche</surname> <given-names>A.</given-names></name> <name><surname>Dovero</surname> <given-names>S.</given-names></name> <name><surname>Arotcarena</surname> <given-names>M.-L.</given-names></name> <name><surname>Camus</surname> <given-names>S.</given-names></name> <name><surname>Porras</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Identification of distinct pathological signatures induced by patient-derived &#x003B1;-synuclein structures in nonhuman primates</article-title>. <source>Sci. Adv.</source> <volume>6</volume>:<fpage>eaaz9165</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.aaz9165</pub-id><pub-id pub-id-type="pmid">32426502</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname> <given-names>H.</given-names></name> <name><surname>de Vos</surname> <given-names>R. A.</given-names></name> <name><surname>Bohl</surname> <given-names>J.</given-names></name> <name><surname>Del Tredici</surname> <given-names>K.</given-names></name></person-group> (<year>2006</year>). <article-title>Gastric &#x003B1;-synuclein immunoreactive inclusions in Meissner&#x02019;s and Auerbach&#x02019;s plexuses in cases staged for Parkinson&#x02019;s disease-related brain pathology</article-title>. <source>Neurosci. Lett.</source> <volume>396</volume>, <fpage>67</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2005.11.012</pub-id><pub-id pub-id-type="pmid">16330147</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname> <given-names>H.</given-names></name> <name><surname>de Vos</surname> <given-names>R. A.</given-names></name> <name><surname>Jansen</surname> <given-names>E. N.</given-names></name> <name><surname>Bratzke</surname> <given-names>H.</given-names></name> <name><surname>Braak</surname> <given-names>E.</given-names></name></person-group> (<year>1998</year>). <article-title>Neuropathological hallmarks of Alzheimer&#x02019;s and Parkinson&#x02019;s diseases</article-title>. <source>Prog. Brain Res.</source> <volume>117</volume>, <fpage>267</fpage>&#x02013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1016/s0079-6123(08)64021-2</pub-id><pub-id pub-id-type="pmid">9932414</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname> <given-names>H.</given-names></name> <name><surname>Ghebremedhin</surname> <given-names>E.</given-names></name> <name><surname>Rub</surname> <given-names>U.</given-names></name> <name><surname>Bratzke</surname> <given-names>H.</given-names></name> <name><surname>Del Tredici</surname> <given-names>K.</given-names></name></person-group> (<year>2004</year>). <article-title>Stages in the development of Parkinson&#x02019;s disease-related pathology</article-title>. <source>Cell Tissue Res.</source> <volume>318</volume>, <fpage>121</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-004-0956-9</pub-id><pub-id pub-id-type="pmid">15338272</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname> <given-names>H.</given-names></name> <name><surname>Rub</surname> <given-names>U.</given-names></name> <name><surname>Sandmann-Keil</surname> <given-names>D.</given-names></name> <name><surname>Gai</surname> <given-names>W. P.</given-names></name> <name><surname>de Vos</surname> <given-names>R. A.</given-names></name> <name><surname>Jansen Steur</surname> <given-names>E. N.</given-names></name> <etal/></person-group>. (<year>2000</year>). <article-title>Parkinson&#x02019;s disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system</article-title>. <source>Acta Neuropathol.</source> <volume>99</volume>, <fpage>489</fpage>&#x02013;<lpage>495</lpage>. <pub-id pub-id-type="doi">10.1007/s004010051150</pub-id><pub-id pub-id-type="pmid">10805091</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000E1;s</surname> <given-names>I. C.</given-names></name> <name><surname>Popova</surname> <given-names>B.</given-names></name> <name><surname>Braus</surname> <given-names>G. H.</given-names></name> <name><surname>Outeiro</surname> <given-names>T. F.</given-names></name></person-group> (<year>2019</year>). <article-title>Yeast-based screens to target &#x003B1;-synuclein toxicity</article-title>. <source>Methods Mol. Biol.</source> <volume>1948</volume>, <fpage>145</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-9124-2_12</pub-id><pub-id pub-id-type="pmid">30771176</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>B&#x000FC;ttner</surname> <given-names>S.</given-names></name> <name><surname>Habernig</surname> <given-names>L.</given-names></name> <name><surname>Broeskamp</surname> <given-names>F.</given-names></name> <name><surname>Ruli</surname> <given-names>D.</given-names></name> <name><surname>V&#x000F6;gtle</surname> <given-names>F. N.</given-names></name> <name><surname>Vlachos</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Endonuclease G mediates &#x003B1;-synuclein cytotoxicity during Parkinson&#x02019;s disease</article-title>. <source>EMBO J.</source> <volume>32</volume>, <fpage>3041</fpage>&#x02013;<lpage>3054</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2013.228</pub-id><pub-id pub-id-type="pmid">24129513</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cackovic</surname> <given-names>J.</given-names></name> <name><surname>Gutierrez-Luke</surname> <given-names>S.</given-names></name> <name><surname>Call</surname> <given-names>G. B.</given-names></name> <name><surname>Juba</surname> <given-names>A.</given-names></name> <name><surname>O&#x02019;Brien</surname> <given-names>S.</given-names></name> <name><surname>Jun</surname> <given-names>C. H.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Vulnerable parkin loss-of-function <italic>Drosophila</italic> dopaminergic neurons have advanced mitochondrial aging, mitochondrial network loss and transiently reduced autophagosome recruitment</article-title>. <source>Front. Cell. Neurosci.</source> <volume>12</volume>:<fpage>39</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2018.00039</pub-id><pub-id pub-id-type="pmid">29497364</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calahorro</surname> <given-names>F.</given-names></name> <name><surname>Ruiz-Rubio</surname> <given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title><italic>Caenorhabditis elegans</italic> as an experimental tool for the study of complex neurological diseases: Parkinson&#x02019;s disease, Alzheimer&#x02019;s disease and autism spectrum disorder</article-title>. <source>Invert. Neurosci.</source> <volume>11</volume>, <fpage>73</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s10158-011-0126-1</pub-id><pub-id pub-id-type="pmid">22068627</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caldwell</surname> <given-names>K. A.</given-names></name> <name><surname>Thies</surname> <given-names>J. L.</given-names></name> <name><surname>Caldwell</surname> <given-names>G. A.</given-names></name></person-group> (<year>2018</year>). <article-title>No Country for old worms: a systematic review of the application of <italic>C. elegans</italic> to investigate a bacterial source of environmental neurotoxicity in Parkinson&#x02019;s disease</article-title>. <source>Metabolites</source> <volume>8</volume>:<fpage>70</fpage>. <pub-id pub-id-type="doi">10.3390/metabo8040070</pub-id><pub-id pub-id-type="pmid">30380609</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname> <given-names>G.-H.</given-names></name> <name><surname>Kim</surname> <given-names>S.</given-names></name> <name><surname>Park</surname> <given-names>J.</given-names></name> <name><surname>Lee</surname> <given-names>E.</given-names></name> <name><surname>Kim</surname> <given-names>M.</given-names></name> <name><surname>Lee</surname> <given-names>S. B.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Parkin negatively regulates JNK pathway in the dopaminergic neurons of <italic>Drosophila</italic></article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>102</volume>, <fpage>10345</fpage>&#x02013;<lpage>10350</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0500346102</pub-id><pub-id pub-id-type="pmid">16002472</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Q.</given-names></name> <name><surname>Ding</surname> <given-names>Q.</given-names></name> <name><surname>Keller</surname> <given-names>J. N.</given-names></name></person-group> (<year>2005a</year>). <article-title>The stationary phase model of aging in yeast for the study of oxidative stress and age-related neurodegeneration</article-title>. <source>Biogerontology</source> <volume>6</volume>, <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1007/s10522-004-7379-6</pub-id><pub-id pub-id-type="pmid">15834659</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Q.</given-names></name> <name><surname>Thorpe</surname> <given-names>J.</given-names></name> <name><surname>Keller</surname> <given-names>J. N.</given-names></name></person-group> (<year>2005b</year>). <article-title>&#x003B1;-Synuclein alters proteasome function, protein synthesis and stationary phase viability</article-title>. <source>J. Biol. Chem.</source> <volume>280</volume>, <fpage>30009</fpage>&#x02013;<lpage>30017</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M501308200</pub-id><pub-id pub-id-type="pmid">15941712</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>L.</given-names></name> <name><surname>Feany</surname> <given-names>M. B.</given-names></name></person-group> (<year>2005</year>). <article-title>&#x003B1;-synuclein phosphorylation controls neurotoxicity and inclusion formation in a <italic>Drosophila</italic> model of Parkinson disease</article-title>. <source>Nat. Neurosci.</source> <volume>8</volume>, <fpage>657</fpage>&#x02013;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1038/nn1443</pub-id><pub-id pub-id-type="pmid">15834418</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname> <given-names>S. J.</given-names></name> <name><surname>Tan</surname> <given-names>E.-K.</given-names></name> <name><surname>Chao</surname> <given-names>Y.-X.</given-names></name></person-group> (<year>2020</year>). <article-title>Historical perspective: models of Parkinson&#x02019;s disease</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>2464</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21072464</pub-id><pub-id pub-id-type="pmid">32252301</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname> <given-names>A. B.</given-names></name> <name><surname>S&#x000F8;rensen</surname> <given-names>J. C. H.</given-names></name> <name><surname>Ettrup</surname> <given-names>K. S.</given-names></name> <name><surname>Orlowski</surname> <given-names>D.</given-names></name> <name><surname>Bjarkam</surname> <given-names>C. R.</given-names></name></person-group> (<year>2018</year>). <article-title>Pirouetting pigs: a large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway</article-title>. <source>Brain Res. Bull.</source> <volume>139</volume>, <fpage>167</fpage>&#x02013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2018.02.010</pub-id><pub-id pub-id-type="pmid">29462643</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>I. E.</given-names></name> <name><surname>Dodson</surname> <given-names>M. W.</given-names></name> <name><surname>Jiang</surname> <given-names>C.</given-names></name> <name><surname>Cao</surname> <given-names>J. H.</given-names></name> <name><surname>Huh</surname> <given-names>J. R.</given-names></name> <name><surname>Seol</surname> <given-names>J. H.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title><italic>Drosophila</italic> pink1 is required for mitochondrial function and interacts genetically with parkin</article-title>. <source>Nature</source> <volume>441</volume>, <fpage>1162</fpage>&#x02013;<lpage>1166</lpage>. <pub-id pub-id-type="doi">10.1038/nature04779</pub-id><pub-id pub-id-type="pmid">16672981</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname> <given-names>J. F.</given-names></name> <name><surname>Van Raamsdonk</surname> <given-names>J. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Modeling Parkinson&#x02019;s disease in <italic>C. elegans</italic></article-title>. <source>J. Parkinsons Dis.</source> <volume>8</volume>, <fpage>17</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.3233/JPD-171258</pub-id><pub-id pub-id-type="pmid">29480229</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coulom</surname> <given-names>H.</given-names></name> <name><surname>Birman</surname> <given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>Chronic exposure to rotenone models sporadic Parkinson&#x02019;s disease in <italic>Drosophila melanogaster</italic></article-title>. <source>J. Neurosci.</source> <volume>24</volume>, <fpage>10993</fpage>&#x02013;<lpage>10998</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2993-04.2004</pub-id><pub-id pub-id-type="pmid">15574749</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cronin</surname> <given-names>A.</given-names></name> <name><surname>Grealy</surname> <given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuroprotective and neuro-restorative effects of minocycline and rasagiline in a zebrafish 6-hydroxydopamine model of Parkinson&#x02019;s disease</article-title>. <source>Neuroscience</source> <volume>367</volume>, <fpage>34</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.10.018</pub-id><pub-id pub-id-type="pmid">29079063</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalf&#x000F3;</surname> <given-names>E.</given-names></name> <name><surname>G&#x000F3;mez-Isla</surname> <given-names>T.</given-names></name> <name><surname>Rosa</surname> <given-names>J. L.</given-names></name> <name><surname>Nieto Bodel&#x000F3;n</surname> <given-names>M.</given-names></name> <name><surname>Cuadrado Tejedor</surname> <given-names>M.</given-names></name> <name><surname>Barrachina</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>Abnormal &#x003B1;-synuclein interactions with Rab proteins in &#x003B1;-synuclein A30P transgenic mice</article-title>. <source>J. Neuropathol. Exp. Neurol.</source> <volume>63</volume>, <fpage>302</fpage>&#x02013;<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1093/jnen/63.4.302</pub-id><pub-id pub-id-type="pmid">15099020</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danek</surname> <given-names>M.</given-names></name> <name><surname>Danek</surname> <given-names>J.</given-names></name> <name><surname>Araszkiewicz</surname> <given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Large animals as potential models of human mental and behavioral disorders</article-title>. <source>Psychiatr. Pol.</source> <volume>51</volume>, <fpage>1009</fpage>&#x02013;<lpage>1027</lpage>. <pub-id pub-id-type="doi">10.12740/PP/74304</pub-id><pub-id pub-id-type="pmid">29432500</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danielsen</surname> <given-names>E. H.</given-names></name> <name><surname>Cumming</surname> <given-names>P.</given-names></name> <name><surname>Andersen</surname> <given-names>F.</given-names></name> <name><surname>Bender</surname> <given-names>D.</given-names></name> <name><surname>Brevig</surname> <given-names>T.</given-names></name> <name><surname>Falborg</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2000</year>). <article-title>The DaNeX study of embryonic mesencephalic, dopaminergic tissue grafted to a minipig model of Parkinson&#x02019;s disease: preliminary findings of effect of MPTP poisoning on striatal dopaminergic markers</article-title>. <source>Cell Transplant.</source> <volume>9</volume>, <fpage>247</fpage>&#x02013;<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1177/096368970000900210</pub-id><pub-id pub-id-type="pmid">10811397</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dauer</surname> <given-names>W.</given-names></name> <name><surname>Przedborski</surname> <given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Parkinson&#x02019;s disease: mechanisms and models</article-title>. <source>Neuron</source> <volume>39</volume>, <fpage>889</fpage>&#x02013;<lpage>909</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(03)00568-3</pub-id><pub-id pub-id-type="pmid">12971891</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deffains</surname> <given-names>M.</given-names></name> <name><surname>Bergman</surname> <given-names>H.</given-names></name></person-group> (<year>2019</year>). <article-title>Parkinsonism-related &#x003B2; oscillations in the primate basal ganglia networks&#x02014;recent advances and clinical implications</article-title>. <source>Parkinsonism Relat. Disord.</source> <volume>59</volume>, <fpage>2</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2018.12.015</pub-id><pub-id pub-id-type="pmid">30578010</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dexter</surname> <given-names>P. M.</given-names></name> <name><surname>Caldwell</surname> <given-names>K. A.</given-names></name> <name><surname>Caldwell</surname> <given-names>G. A.</given-names></name></person-group> (<year>2012</year>). <article-title>A predictable worm: application of <italic>Caenorhabditis elegans</italic> for mechanistic investigation of movement disorders</article-title>. <source>Neurotherapeutics</source> <volume>9</volume>, <fpage>393</fpage>&#x02013;<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-012-0109-x</pub-id><pub-id pub-id-type="pmid">22403010</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dunham</surname> <given-names>M. J.</given-names></name> <name><surname>Fowler</surname> <given-names>D. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Contemporary, yeast-based approaches to understanding human genetic variation</article-title>. <source>Curr. Opin. Genet. Dev.</source> <volume>23</volume>, <fpage>658</fpage>&#x02013;<lpage>664</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2013.10.001</pub-id><pub-id pub-id-type="pmid">24252429</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname> <given-names>L. L.</given-names></name> <name><surname>Quigley</surname> <given-names>E. M.</given-names></name> <name><surname>Pfeiffer</surname> <given-names>R. F.</given-names></name></person-group> (<year>1992</year>). <article-title>Gastrointestinal dysfunction in Parkinson&#x02019;s disease: frequency and pathophysiology</article-title>. <source>Neurology</source> <volume>42</volume>, <fpage>726</fpage>&#x02013;<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.42.4.726</pub-id><pub-id pub-id-type="pmid">1565224</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elbaz</surname> <given-names>A.</given-names></name> <name><surname>Carcaillon</surname> <given-names>L.</given-names></name> <name><surname>Kab</surname> <given-names>S.</given-names></name> <name><surname>Moisan</surname> <given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Epidemiology of Parkinson&#x02019;s disease</article-title>. <source>Rev. Neurol.</source> <volume>172</volume>, <fpage>14</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurol.2015.09.012</pub-id><pub-id pub-id-type="pmid">26718594</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elfil</surname> <given-names>M.</given-names></name> <name><surname>Kamel</surname> <given-names>S.</given-names></name> <name><surname>Kandil</surname> <given-names>M.</given-names></name> <name><surname>Koo</surname> <given-names>B. B.</given-names></name> <name><surname>Schaefer</surname> <given-names>S. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Implications of the gut microbiome in Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>35</volume>, <fpage>921</fpage>&#x02013;<lpage>933</lpage>. <pub-id pub-id-type="doi">10.1002/mds.28004</pub-id><pub-id pub-id-type="pmid">32092186</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faggiani</surname> <given-names>E.</given-names></name> <name><surname>Benazzouz</surname> <given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Deep brain stimulation of the subthalamic nucleus in Parkinson&#x02019;s disease: from history to the interaction with the monoaminergic systems</article-title>. <source>Prog. Neurobiol.</source> <volume>151</volume>, <fpage>139</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2016.07.003</pub-id><pub-id pub-id-type="pmid">27412110</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faria</surname> <given-names>C.</given-names></name> <name><surname>Jorge</surname> <given-names>C. D.</given-names></name> <name><surname>Borges</surname> <given-names>N.</given-names></name> <name><surname>Tenreiro</surname> <given-names>S.</given-names></name> <name><surname>Outeiro</surname> <given-names>T. F.</given-names></name> <name><surname>Santos</surname> <given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Inhibition of formation of &#x003B1;-synuclein inclusions by mannosylglycerate in a yeast model of Parkinson&#x02019;s disease</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1830</volume>, <fpage>4065</fpage>&#x02013;<lpage>4072</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2013.04.015</pub-id><pub-id pub-id-type="pmid">23608058</pub-id></citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farias</surname> <given-names>F. H.</given-names></name> <name><surname>Zeng</surname> <given-names>R.</given-names></name> <name><surname>Johnson</surname> <given-names>G. S.</given-names></name> <name><surname>Wininger</surname> <given-names>F. A.</given-names></name> <name><surname>Taylor</surname> <given-names>J. F.</given-names></name> <name><surname>Schnabel</surname> <given-names>R. D.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers</article-title>. <source>Neurobiol. Dis.</source> <volume>42</volume>, <fpage>468</fpage>&#x02013;<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2011.02.009</pub-id><pub-id pub-id-type="pmid">21362476</pub-id></citation></ref>
<ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feany</surname> <given-names>M. B.</given-names></name> <name><surname>Bender</surname> <given-names>W. W.</given-names></name></person-group> (<year>2000</year>). <article-title>A <italic>Drosophila</italic> model of Parkinson&#x02019;s disease</article-title>. <source>Nature</source> <volume>404</volume>, <fpage>394</fpage>&#x02013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1038/35006074</pub-id><pub-id pub-id-type="pmid">10746727</pub-id></citation></ref>
<ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>C.-W.</given-names></name> <name><surname>Chen</surname> <given-names>N.-F.</given-names></name> <name><surname>Sung</surname> <given-names>C.-S.</given-names></name> <name><surname>Kuo</surname> <given-names>H.-M.</given-names></name> <name><surname>Yang</surname> <given-names>S.-N.</given-names></name> <name><surname>Chen</surname> <given-names>C.-L.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Therapeutic effect of modulating TREM-1 <italic>via</italic> anti-inflammation and autophagy in Parkinson&#x02019;s disease</article-title>. <source>Front. Neurosci.</source> <volume>13</volume>:<fpage>769</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2019.00769</pub-id><pub-id pub-id-type="pmid">31440123</pub-id></citation></ref>
<ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>C.-W.</given-names></name> <name><surname>Hung</surname> <given-names>H.-C.</given-names></name> <name><surname>Huang</surname> <given-names>S.-Y.</given-names></name> <name><surname>Chen</surname> <given-names>C.-H.</given-names></name> <name><surname>Chen</surname> <given-names>Y.-R.</given-names></name> <name><surname>Chen</surname> <given-names>C.-Y.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Neuroprotective effect of the marine-derived compound 11-dehydrosinulariolide through DJ-1-related pathway in <italic>in vitro</italic> and <italic>in vivo</italic> models of Parkinson&#x02019;s disease</article-title>. <source>Mar. Drugs</source> <volume>14</volume>:<fpage>187</fpage>. <pub-id pub-id-type="doi">10.3390/md14100187</pub-id><pub-id pub-id-type="pmid">27763504</pub-id></citation></ref>
<ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fiandaca</surname> <given-names>M. S.</given-names></name> <name><surname>Bankiewicz</surname> <given-names>K. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Gene therapy for Parkinson&#x02019;s disease: from non-human primates to humans</article-title>. <source>Curr. Opin. Mol. Ther.</source> <volume>12</volume>, <fpage>519</fpage>&#x02013;<lpage>529</lpage>. <pub-id pub-id-type="pmid">20886383</pub-id></citation></ref>
<ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fifel</surname> <given-names>K.</given-names></name> <name><surname>Vezoli</surname> <given-names>J.</given-names></name> <name><surname>Dzahini</surname> <given-names>K.</given-names></name> <name><surname>Claustrat</surname> <given-names>B.</given-names></name> <name><surname>Leviel</surname> <given-names>V.</given-names></name> <name><surname>Kennedy</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>e86240</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0086240</pub-id><pub-id pub-id-type="pmid">24465981</pub-id></citation></ref>
<ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Firnhaber</surname> <given-names>C.</given-names></name> <name><surname>Hammarlund</surname> <given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuron-specific feeding RNAi in <italic>C. elegans</italic> and its use in a screen for essential genes required for GABA neuron function</article-title>. <source>PLoS Genet.</source> <volume>9</volume>:<fpage>e1003921</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1003921</pub-id><pub-id pub-id-type="pmid">24244189</pub-id></citation></ref>
<ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flower</surname> <given-names>T. R.</given-names></name> <name><surname>Chesnokova</surname> <given-names>L. S.</given-names></name> <name><surname>Froelich</surname> <given-names>C. A.</given-names></name> <name><surname>Dixon</surname> <given-names>C.</given-names></name> <name><surname>Witt</surname> <given-names>S. N.</given-names></name></person-group> (<year>2005</year>). <article-title>Heat shock prevents &#x003B1;-synuclein-induced apoptosis in a yeast model of Parkinson&#x02019;s disease</article-title>. <source>J. Mol. Biol.</source> <volume>351</volume>, <fpage>1081</fpage>&#x02013;<lpage>1100</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2005.06.060</pub-id><pub-id pub-id-type="pmid">16051265</pub-id></citation></ref>
<ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname> <given-names>M. R.</given-names></name></person-group> (<year>2015</year>). <article-title><italic>Drosophila</italic> central nervous system glia</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>7</volume>:<fpage>a020552</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a020552</pub-id><pub-id pub-id-type="pmid">25722465</pub-id></citation></ref>
<ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gade</surname> <given-names>V. R.</given-names></name> <name><surname>Kardani</surname> <given-names>J.</given-names></name> <name><surname>Roy</surname> <given-names>I.</given-names></name></person-group> (<year>2014</year>). <article-title>Effect of endogenous Hsp104 chaperone in yeast models of sporadic and familial Parkinson&#x02019;s disease</article-title>. <source>Int. J. Biochem. Cell Biol.</source> <volume>55</volume>, <fpage>87</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2014.08.013</pub-id><pub-id pub-id-type="pmid">25161148</pub-id></citation></ref>
<ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaeta</surname> <given-names>A. L.</given-names></name> <name><surname>Caldwell</surname> <given-names>K. A.</given-names></name> <name><surname>Caldwell</surname> <given-names>G. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Found in translation: the utility of <italic>C. elegans</italic> &#x003B1;-synuclein models of Parkinson&#x02019;s disease</article-title>. <source>Brain Sci.</source> <volume>9</volume>:<fpage>73</fpage>. <pub-id pub-id-type="doi">10.3390/brainsci9040073</pub-id><pub-id pub-id-type="pmid">30925741</pub-id></citation></ref>
<ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>X.</given-names></name> <name><surname>Carroni</surname> <given-names>M.</given-names></name> <name><surname>Nussbaum-Krammer</surname> <given-names>C.</given-names></name> <name><surname>Mogk</surname> <given-names>A.</given-names></name> <name><surname>Nillegoda</surname> <given-names>N. B.</given-names></name> <name><surname>Szlachcic</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Human Hsp70 disaggregase reverses Parkinson&#x02019;s-linked &#x003B1;-synuclein amyloid fibrils</article-title>. <source>Mol. Cell</source> <volume>59</volume>, <fpage>781</fpage>&#x02013;<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2015.07.012</pub-id><pub-id pub-id-type="pmid">26300264</pub-id></citation></ref>
<ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Moreno</surname> <given-names>J. C.</given-names></name> <name><surname>Porta de la Riva</surname> <given-names>M.</given-names></name> <name><surname>Mart&#x000ED;nez-Lara</surname> <given-names>E.</given-names></name> <name><surname>Siles</surname> <given-names>E.</given-names></name> <name><surname>Ca&#x000F1;uelo</surname> <given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Tyrosol, a simple phenol from EVOO, targets multiple pathogenic mechanisms of neurodegeneration in a <italic>C. elegans</italic> model of Parkinson&#x02019;s disease</article-title>. <source>Neurobiol. Aging</source> <volume>82</volume>, <fpage>60</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.07.003</pub-id><pub-id pub-id-type="pmid">31404721</pub-id></citation></ref>
<ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghatak</surname> <given-names>S.</given-names></name> <name><surname>Trudler</surname> <given-names>D.</given-names></name> <name><surname>Dolatabadi</surname> <given-names>N.</given-names></name> <name><surname>Ambasudhan</surname> <given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>Parkinson&#x02019;s disease: what the model systems have taught us so far</article-title>. <source>J. Genet.</source> <volume>97</volume>, <fpage>729</fpage>&#x02013;<lpage>751</lpage>. <pub-id pub-id-type="doi">10.1007/s12041-018-0960-6</pub-id><pub-id pub-id-type="pmid">30027906</pub-id></citation></ref>
<ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x000F3;mez-Benito</surname> <given-names>M.</given-names></name> <name><surname>Granado</surname> <given-names>N.</given-names></name> <name><surname>Garc&#x000ED;a-Sanz</surname> <given-names>P.</given-names></name> <name><surname>Michel</surname> <given-names>A.</given-names></name> <name><surname>Dumoulin</surname> <given-names>M.</given-names></name> <name><surname>Moratalla</surname> <given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Modeling Parkinson&#x02019;s disease with the &#x003B1;-synuclein protein</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>:<fpage>356</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00356</pub-id><pub-id pub-id-type="pmid">32390826</pub-id></citation></ref>
<ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname> <given-names>J. C.</given-names></name> <name><surname>Whitworth</surname> <given-names>A. J.</given-names></name> <name><surname>Kuo</surname> <given-names>I.</given-names></name> <name><surname>Andrews</surname> <given-names>L. A.</given-names></name> <name><surname>Feany</surname> <given-names>M. B.</given-names></name> <name><surname>Pallanck</surname> <given-names>L. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Mitochondrial pathology and apoptotic muscle degeneration in <italic>Drosophila</italic> parkin mutants</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>100</volume>, <fpage>4078</fpage>&#x02013;<lpage>4083</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0737556100</pub-id><pub-id pub-id-type="pmid">12642658</pub-id></citation></ref>
<ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Griffioen</surname> <given-names>G.</given-names></name> <name><surname>Duhamel</surname> <given-names>H.</given-names></name> <name><surname>Van Damme</surname> <given-names>N.</given-names></name> <name><surname>Pellens</surname> <given-names>K.</given-names></name> <name><surname>Zabrocki</surname> <given-names>P.</given-names></name> <name><surname>Pannecouque</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>A yeast-based model of &#x003B1;-synucleinopathy identifies compounds with therapeutic potential</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1762</volume>, <fpage>312</fpage>&#x02013;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2005.11.009</pub-id><pub-id pub-id-type="pmid">16413174</pub-id></citation></ref>
<ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gr&#x000FC;nblatt</surname> <given-names>E.</given-names></name> <name><surname>Ruder</surname> <given-names>J.</given-names></name> <name><surname>Monoranu</surname> <given-names>C. M.</given-names></name> <name><surname>Riederer</surname> <given-names>P.</given-names></name> <name><surname>Youdim</surname> <given-names>M. B.</given-names></name> <name><surname>Mandel</surname> <given-names>S. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Differential alterations in metabolism and proteolysis-related proteins in human Parkinson&#x02019;s disease substantia nigra</article-title>. <source>Neurotox Res.</source> <volume>33</volume>, <fpage>560</fpage>&#x02013;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-017-9843-5</pub-id><pub-id pub-id-type="pmid">29218503</pub-id></citation></ref>
<ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hijaz</surname> <given-names>B. A.</given-names></name> <name><surname>Volpicelli-Daley</surname> <given-names>L. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Initiation and propagation of &#x003B1;-synuclein aggregation in the nervous system</article-title>. <source>Mol. Neurodegener.</source> <volume>15</volume>:<fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s13024-020-00368-6</pub-id><pub-id pub-id-type="pmid">32143659</pub-id></citation></ref>
<ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hogg</surname> <given-names>M. C.</given-names></name> <name><surname>Prehn</surname> <given-names>J. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Endonuclease-G and the pathways to dopaminergic neurodegeneration: a question of location?</article-title> <source>EMBO J.</source> <volume>32</volume>, <fpage>3014</fpage>&#x02013;<lpage>3016</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2013.238</pub-id><pub-id pub-id-type="pmid">24162725</pub-id></citation></ref>
<ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname> <given-names>D. G.</given-names></name> <name><surname>Bradford</surname> <given-names>Y. M.</given-names></name> <name><surname>Conlin</surname> <given-names>T.</given-names></name> <name><surname>Eagle</surname> <given-names>A. E.</given-names></name> <name><surname>Fashena</surname> <given-names>D.</given-names></name> <name><surname>Frazer</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>ZFIN, the zebrafish model organism database: increased support for mutants and transgenics</article-title>. <source>Nucleic Acids Res.</source> <volume>41</volume>, <fpage>D854</fpage>&#x02013;<lpage>D860</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks938</pub-id><pub-id pub-id-type="pmid">23074187</pub-id></citation></ref>
<ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname> <given-names>K.</given-names></name> <name><surname>Clark</surname> <given-names>M. D.</given-names></name> <name><surname>Torroja</surname> <given-names>C. F.</given-names></name> <name><surname>Torrance</surname> <given-names>J.</given-names></name> <name><surname>Berthelot</surname> <given-names>C.</given-names></name> <name><surname>Muffato</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>The zebrafish reference genome sequence and its relationship to the human genome</article-title>. <source>Nature</source> <volume>496</volume>, <fpage>498</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1038/nature12111</pub-id><pub-id pub-id-type="pmid">23594743</pub-id></citation></ref>
<ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Z.-Y.</given-names></name> <name><surname>Chen</surname> <given-names>B.</given-names></name> <name><surname>Zhang</surname> <given-names>J.-P.</given-names></name> <name><surname>Ma</surname> <given-names>Y.-Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Up-regulation of autophagy-related gene 5 (ATG5) protects dopaminergic neurons in a zebrafish model of Parkinson&#x02019;s disease</article-title>. <source>J. Biol. Chem.</source> <volume>292</volume>, <fpage>18062</fpage>&#x02013;<lpage>18074</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.764795</pub-id><pub-id pub-id-type="pmid">28928221</pub-id></citation></ref>
<ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname> <given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>PINK1-Parkin signaling in Parkinson&#x02019;s disease: lessons from <italic>Drosophila</italic></article-title>. <source>Neurosci. Res.</source> <volume>159</volume>, <fpage>40</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.neures.2020.01.016</pub-id><pub-id pub-id-type="pmid">32035987</pub-id></citation></ref>
<ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname> <given-names>Y.</given-names></name> <name><surname>Gehrke</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>H.-Q.</given-names></name> <name><surname>Takahashi</surname> <given-names>R.</given-names></name> <name><surname>Hasegawa</surname> <given-names>K.</given-names></name> <name><surname>Oota</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in <italic>Drosophila</italic></article-title>. <source>EMBO J.</source> <volume>27</volume>, <fpage>2432</fpage>&#x02013;<lpage>2443</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2008.163</pub-id><pub-id pub-id-type="pmid">18701920</pub-id></citation></ref>
<ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jadiya</surname> <given-names>P.</given-names></name> <name><surname>Nazir</surname> <given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Environmental toxicants as extrinsic epigenetic factors for parkinsonism: studies employing transgenic <italic>C. elegans</italic> model</article-title>. <source>CNS Neurol. Disord. Drug Targets</source> <volume>11</volume>, <fpage>976</fpage>&#x02013;<lpage>983</lpage>. <pub-id pub-id-type="doi">10.2174/1871527311211080006</pub-id><pub-id pub-id-type="pmid">23244436</pub-id></citation></ref>
<ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname> <given-names>J.</given-names></name></person-group> (<year>2008a</year>). <article-title>Parkinson&#x02019;s disease and movement disorders: moving forward</article-title>. <source>Lancet Neurol.</source> <volume>7</volume>, <fpage>9</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(07)70302-2</pub-id><pub-id pub-id-type="pmid">18093549</pub-id></citation></ref>
<ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname> <given-names>J.</given-names></name></person-group> (<year>2008b</year>). <article-title>Parkinson&#x02019;s disease: clinical features and diagnosis</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source> <volume>79</volume>, <fpage>368</fpage>&#x02013;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.2007.131045</pub-id><pub-id pub-id-type="pmid">18344392</pub-id></citation></ref>
<ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname> <given-names>T. M.</given-names></name> <name><surname>Fox</surname> <given-names>S. H.</given-names></name></person-group> (<year>2015</year>). <article-title>Symptomatic models of Parkinson&#x02019;s disease and L-DOPA-induced dyskinesia in non-human primates</article-title>. <source>Curr. Top. Behav. Neurosci.</source> <volume>22</volume>, <fpage>221</fpage>&#x02013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1007/7854_2014_352</pub-id><pub-id pub-id-type="pmid">25158623</pub-id></citation></ref>
<ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahana</surname> <given-names>M.</given-names></name> <name><surname>Weizman</surname> <given-names>A.</given-names></name> <name><surname>Gabay</surname> <given-names>M.</given-names></name> <name><surname>Loboda</surname> <given-names>Y.</given-names></name> <name><surname>Segal-Gavish</surname> <given-names>H.</given-names></name> <name><surname>Gavish</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson&#x02019;s disease</article-title>. <source>Mol. Psychiatry</source> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1038/s41380-020-0742-4</pub-id><pub-id pub-id-type="pmid">32372010</pub-id></citation></ref>
<ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kin</surname> <given-names>K.</given-names></name> <name><surname>Yasuhara</surname> <given-names>T.</given-names></name> <name><surname>Kameda</surname> <given-names>M.</given-names></name> <name><surname>Date</surname> <given-names>I.</given-names></name></person-group> (<year>2019</year>). <article-title>Animal models for Parkinson&#x02019;s disease research: trends in the 2,000 s</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume>:<fpage>5402</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20215402</pub-id><pub-id pub-id-type="pmid">31671557</pub-id></citation></ref>
<ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname> <given-names>J. H.</given-names></name> <name><surname>Spetsieris</surname> <given-names>P. G.</given-names></name> <name><surname>Eidelberg</surname> <given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>Network structure and function in Parkinson&#x02019;s disease</article-title>. <source>Cereb. Cortex</source> <volume>28</volume>, <fpage>4121</fpage>&#x02013;<lpage>4135</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhx267</pub-id><pub-id pub-id-type="pmid">29088324</pub-id></citation></ref>
<ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koprich</surname> <given-names>J. B.</given-names></name> <name><surname>Johnston</surname> <given-names>T. H.</given-names></name> <name><surname>Reyes</surname> <given-names>G.</given-names></name> <name><surname>Omana</surname> <given-names>V.</given-names></name> <name><surname>Brotchie</surname> <given-names>J. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Towards a non-human primate model of &#x003B1;-synucleinopathy for development of therapeutics for Parkinson&#x02019;s disease: optimization of AAV1/2 delivery parameters to drive sustained expression of &#x003B1; synuclein and dopaminergic degeneration in macaque</article-title>. <source>PLoS One</source> <volume>11</volume>:<fpage>e0167235</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0167235</pub-id><pub-id pub-id-type="pmid">27902767</pub-id></citation></ref>
<ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kritzer</surname> <given-names>J. A.</given-names></name> <name><surname>Hamamichi</surname> <given-names>S.</given-names></name> <name><surname>McCaffery</surname> <given-names>J. M.</given-names></name> <name><surname>Santagata</surname> <given-names>S.</given-names></name> <name><surname>Naumann</surname> <given-names>T. A.</given-names></name> <name><surname>Caldwell</surname> <given-names>K. A.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Rapid selection of cyclic peptides that reduce &#x003B1;-synuclein toxicity in yeast and animal models</article-title>. <source>Nat. Chem. Biol.</source> <volume>5</volume>, <fpage>655</fpage>&#x02013;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.193</pub-id><pub-id pub-id-type="pmid">19597508</pub-id></citation></ref>
<ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuwahara</surname> <given-names>T.</given-names></name> <name><surname>Koyama</surname> <given-names>A.</given-names></name> <name><surname>Gengyo-Ando</surname> <given-names>K.</given-names></name> <name><surname>Masuda</surname> <given-names>M.</given-names></name> <name><surname>Kowa</surname> <given-names>H.</given-names></name> <name><surname>Tsunoda</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>Familial Parkinson mutant &#x003B1;-synuclein causes dopamine neuron dysfunction in transgenic <italic>Caenorhabditis elegans</italic></article-title>. <source>J. Biol. Chem.</source> <volume>281</volume>, <fpage>334</fpage>&#x02013;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M504860200</pub-id><pub-id pub-id-type="pmid">16260788</pub-id></citation></ref>
<ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lakso</surname> <given-names>M.</given-names></name> <name><surname>Vartiainen</surname> <given-names>S.</given-names></name> <name><surname>Moilanen</surname> <given-names>A.-M.</given-names></name> <name><surname>Sirvi&#x000F6;</surname> <given-names>J.</given-names></name> <name><surname>Thomas</surname> <given-names>J. H.</given-names></name> <name><surname>Nass</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2003</year>). <article-title>Dopaminergic neuronal loss and motor deficits in <italic>Caenorhabditis elegans</italic> overexpressing human &#x003B1;-synuclein</article-title>. <source>J. Neurochem.</source> <volume>86</volume>, <fpage>165</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01809.x</pub-id><pub-id pub-id-type="pmid">12807436</pub-id></citation></ref>
<ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langston</surname> <given-names>R. G.</given-names></name> <name><surname>Rudenko</surname> <given-names>I. N.</given-names></name> <name><surname>Cookson</surname> <given-names>M. R.</given-names></name></person-group> (<year>2016</year>). <article-title>The function of orthologues of the human Parkinson&#x02019;s disease gene LRRK2 across species: implications for disease modelling in preclinical research</article-title>. <source>Biochem. J.</source> <volume>473</volume>, <fpage>221</fpage>&#x02013;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20150985</pub-id><pub-id pub-id-type="pmid">26811536</pub-id></citation></ref>
<ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>S. B.</given-names></name> <name><surname>Kim</surname> <given-names>W.</given-names></name> <name><surname>Lee</surname> <given-names>S.</given-names></name> <name><surname>Chung</surname> <given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in <italic>Drosophila</italic></article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>358</volume>, <fpage>534</fpage>&#x02013;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2007.04.156</pub-id><pub-id pub-id-type="pmid">17498648</pub-id></citation></ref>
<ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>M. K.</given-names></name> <name><surname>Stirling</surname> <given-names>W.</given-names></name> <name><surname>Xu</surname> <given-names>Y.</given-names></name> <name><surname>Xu</surname> <given-names>X.</given-names></name> <name><surname>Qui</surname> <given-names>D.</given-names></name> <name><surname>Mandir</surname> <given-names>A. S.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Human &#x003B1;-synuclein-harboring familial Parkinson&#x02019;s disease-linked Ala-53 &#x02013;> Thr mutation causes neurodegenerative disease with &#x003B1;-synuclein aggregation in transgenic mice</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>99</volume>, <fpage>8968</fpage>&#x02013;<lpage>8973</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.132197599</pub-id><pub-id pub-id-type="pmid">12084935</pub-id></citation></ref>
<ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehtonen</surname> <given-names>&#x00160;.</given-names></name> <name><surname>Jaronen</surname> <given-names>M.</given-names></name> <name><surname>Vehvil&#x000E4;inen</surname> <given-names>P.</given-names></name> <name><surname>Lakso</surname> <given-names>M.</given-names></name> <name><surname>Rudgalvyte</surname> <given-names>M.</given-names></name> <name><surname>Keksa-Goldsteine</surname> <given-names>V.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Inhibition of excessive oxidative protein folding is protective in MPP(+) toxicity-induced Parkinson&#x02019;s disease models</article-title>. <source>Antioxid. Redox Signal.</source> <volume>25</volume>, <fpage>485</fpage>&#x02013;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2015.6402</pub-id><pub-id pub-id-type="pmid">27139804</pub-id></citation></ref>
<ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Liu</surname> <given-names>B.</given-names></name> <name><surname>Li</surname> <given-names>X.-L.</given-names></name> <name><surname>Li</surname> <given-names>Y.-X.</given-names></name> <name><surname>Sun</surname> <given-names>M.-Z.</given-names></name> <name><surname>Chen</surname> <given-names>D.-Y.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>SiO2 nanoparticles change colour preference and cause Parkinson&#x02019;s-like behaviour in zebrafish</article-title>. <source>Sci. Rep.</source> <volume>4</volume>:<fpage>3810</fpage>. <pub-id pub-id-type="doi">10.1038/srep03810</pub-id><pub-id pub-id-type="pmid">24448416</pub-id></citation></ref>
<ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>C.</given-names></name> <name><surname>Tang</surname> <given-names>B.</given-names></name> <name><surname>Feng</surname> <given-names>Y.</given-names></name> <name><surname>Tang</surname> <given-names>F.</given-names></name> <name><surname>Pui-Man Hoi</surname> <given-names>M.</given-names></name> <name><surname>Su</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Pinostrobin exerts neuroprotective actions in neurotoxin-induced Parkinson&#x02019;s disease models through Nrf2 induction</article-title>. <source>J. Agric. Food Chem.</source> <volume>66</volume>, <fpage>8307</fpage>&#x02013;<lpage>8318</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.8b02607</pub-id><pub-id pub-id-type="pmid">29961319</pub-id></citation></ref>
<ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>J.</given-names></name> <name><surname>Clark-Dixon</surname> <given-names>C.</given-names></name> <name><surname>Wang</surname> <given-names>S.</given-names></name> <name><surname>Flower</surname> <given-names>T. R.</given-names></name> <name><surname>Williams-Hart</surname> <given-names>T.</given-names></name> <name><surname>Zweig</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Novel suppressors of &#x003B1;-synuclein toxicity identified using yeast</article-title>. <source>Hum. Mol. Genet.</source> <volume>17</volume>, <fpage>3784</fpage>&#x02013;<lpage>3795</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddn276</pub-id><pub-id pub-id-type="pmid">18772193</pub-id></citation></ref>
<ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lillethorup</surname> <given-names>T. P.</given-names></name> <name><surname>Glud</surname> <given-names>A. N.</given-names></name> <name><surname>Alstrup</surname> <given-names>A. K. O.</given-names></name> <name><surname>Mikkelsen</surname> <given-names>T. W.</given-names></name> <name><surname>Nielsen</surname> <given-names>E. H.</given-names></name> <name><surname>Zaer</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs</article-title>. <source>Exp. Neurol.</source> <volume>303</volume>, <fpage>142</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2018.02.005</pub-id><pub-id pub-id-type="pmid">29428213</pub-id></citation></ref>
<ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>Y.</given-names></name> <name><surname>Zou</surname> <given-names>Y.</given-names></name> <name><surname>Lin</surname> <given-names>J.</given-names></name> <name><surname>Zhang</surname> <given-names>T.</given-names></name> <name><surname>Deng</surname> <given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration <italic>via</italic> a newly developed patch</article-title>. <source>Xenobiotica</source> <volume>43</volume>, <fpage>705</fpage>&#x02013;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.3109/00498254.2012.758396</pub-id><pub-id pub-id-type="pmid">23339547</pub-id></citation></ref>
<ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>M.</given-names></name> <name><surname>Yu</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Qiao</surname> <given-names>J.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Ginseng protein protects against mitochondrial dysfunction and neurodegeneration by inducing mitochondrial unfolded protein response in <italic>Drosophila melanogaster</italic> PINK1 model of Parkinson&#x02019;s disease</article-title>. <source>J. Ethnopharmacol.</source> <volume>247</volume>:<fpage>112213</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2019.112213</pub-id><pub-id pub-id-type="pmid">31562951</pub-id></citation></ref>
<ref id="B92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Yu</surname> <given-names>Y.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>T.</given-names></name> <name><surname>Jiang</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>A <italic>Drosophila</italic> model for LRRK2-linked parkinsonism</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>105</volume>, <fpage>2693</fpage>&#x02013;<lpage>2698</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0708452105</pub-id><pub-id pub-id-type="pmid">18258746</pub-id></citation></ref>
<ref id="B93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lotankar</surname> <given-names>S.</given-names></name> <name><surname>Prabhavalkar</surname> <given-names>K. S.</given-names></name> <name><surname>Bhatt</surname> <given-names>L. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Biomarkers for Parkinson&#x02019;s disease: recent advancement</article-title>. <source>Neurosci. Bull.</source> <volume>33</volume>, <fpage>585</fpage>&#x02013;<lpage>597</lpage>. <pub-id pub-id-type="doi">10.1007/s12264-017-0183-5</pub-id><pub-id pub-id-type="pmid">28936761</pub-id></citation></ref>
<ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lulla</surname> <given-names>A.</given-names></name> <name><surname>Barnhill</surname> <given-names>L.</given-names></name> <name><surname>Bitan</surname> <given-names>G.</given-names></name> <name><surname>Ivanova</surname> <given-names>M. I.</given-names></name> <name><surname>Nguyen</surname> <given-names>B.</given-names></name> <name><surname>O&#x02019;Donnell</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Neurotoxicity of the Parkinson disease-associated pesticide ziram is synuclein-dependent in zebrafish embryos</article-title>. <source>Environ. Health Perspect.</source> <volume>124</volume>, <fpage>1766</fpage>&#x02013;<lpage>1775</lpage>. <pub-id pub-id-type="doi">10.1289/EHP141</pub-id><pub-id pub-id-type="pmid">27301718</pub-id></citation></ref>
<ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>L.</given-names></name> <name><surname>Zhao</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>Y.</given-names></name> <name><surname>Cheng</surname> <given-names>B.</given-names></name> <name><surname>Peng</surname> <given-names>A.</given-names></name> <name><surname>Huang</surname> <given-names>K.</given-names></name></person-group> (<year>2018</year>). <article-title><italic>Caenorhabditis elegans</italic> as a model system for target identification and drug screening against neurodegenerative diseases</article-title>. <source>Eur. J. Pharmacol.</source> <volume>819</volume>, <fpage>169</fpage>&#x02013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2017.11.051</pub-id><pub-id pub-id-type="pmid">29208474</pub-id></citation></ref>
<ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macedo</surname> <given-names>D.</given-names></name> <name><surname>Jardim</surname> <given-names>C.</given-names></name> <name><surname>Figueira</surname> <given-names>I.</given-names></name> <name><surname>Almeida</surname> <given-names>A. F.</given-names></name> <name><surname>McDougall</surname> <given-names>G. J.</given-names></name> <name><surname>Stewart</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>(Poly)phenol-digested metabolites modulate &#x003B1;-synuclein toxicity by regulating proteostasis</article-title>. <source>Sci. Rep.</source> <volume>8</volume>:<fpage>6965</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-25118-z</pub-id><pub-id pub-id-type="pmid">29725038</pub-id></citation></ref>
<ref id="B97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname> <given-names>S.</given-names></name> <name><surname>Grunblatt</surname> <given-names>E.</given-names></name> <name><surname>Riederer</surname> <given-names>P.</given-names></name> <name><surname>Amariglio</surname> <given-names>N.</given-names></name> <name><surname>Jacob-Hirsch</surname> <given-names>J.</given-names></name> <name><surname>Rechavi</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Gene expression profiling of sporadic Parkinson&#x02019;s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70</article-title>. <source>Ann. N Y Acad. Sci.</source> <volume>1053</volume>, <fpage>356</fpage>&#x02013;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1344.031</pub-id><pub-id pub-id-type="pmid">16179542</pub-id></citation></ref>
<ref id="B98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manfredsson</surname> <given-names>F. P.</given-names></name> <name><surname>Luk</surname> <given-names>K. C.</given-names></name> <name><surname>Benskey</surname> <given-names>M. J.</given-names></name> <name><surname>Gezer</surname> <given-names>A.</given-names></name> <name><surname>Garcia</surname> <given-names>J.</given-names></name> <name><surname>Kuhn</surname> <given-names>N. C.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Induction of &#x003B1;-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology</article-title>. <source>Neurobiol. Dis.</source> <volume>112</volume>, <fpage>106</fpage>&#x02013;<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2018.01.008</pub-id><pub-id pub-id-type="pmid">29341898</pub-id></citation></ref>
<ref id="B99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname> <given-names>B. A.</given-names></name> <name><surname>Caldwell</surname> <given-names>K. A.</given-names></name> <name><surname>Caldwell</surname> <given-names>G. A.</given-names></name></person-group> (<year>2017</year>). <article-title><italic>C. elegans</italic> as a model system to accelerate discovery for Parkinson disease</article-title>. <source>Curr. Opin. Genet. Dev.</source> <volume>44</volume>, <fpage>102</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2017.02.011</pub-id><pub-id pub-id-type="pmid">28242493</pub-id></citation></ref>
<ref id="B100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname> <given-names>H.</given-names></name> <name><surname>Takahashi</surname> <given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>Parkinson&#x02019;s disease pathogenesis from the viewpoint of small fish models</article-title>. <source>J. Neural Transm.</source> <volume>125</volume>, <fpage>25</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-017-1772-1</pub-id><pub-id pub-id-type="pmid">28770388</pub-id></citation></ref>
<ref id="B101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname> <given-names>H.</given-names></name> <name><surname>Gavinio</surname> <given-names>R.</given-names></name> <name><surname>Takahashi</surname> <given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Medaka fish Parkinson&#x02019;s disease model</article-title>. <source>Exp. Neurobiol.</source> <volume>21</volume>, <fpage>94</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.5607/en.2012.21.3.94</pub-id><pub-id pub-id-type="pmid">23055787</pub-id></citation></ref>
<ref id="B102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname> <given-names>H.</given-names></name> <name><surname>Gavinio</surname> <given-names>R.</given-names></name> <name><surname>Asano</surname> <given-names>T.</given-names></name> <name><surname>Uemura</surname> <given-names>N.</given-names></name> <name><surname>Ito</surname> <given-names>H.</given-names></name> <name><surname>Taniguchi</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2013a</year>). <article-title>PINK1 and Parkin complementarily protect dopaminergic neurons in vertebrates</article-title>. <source>Hum. Mol. Genet.</source> <volume>22</volume>, <fpage>2423</fpage>&#x02013;<lpage>2434</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddt095</pub-id><pub-id pub-id-type="pmid">23449626</pub-id></citation></ref>
<ref id="B103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname> <given-names>H.</given-names></name> <name><surname>Sato</surname> <given-names>F.</given-names></name> <name><surname>Sato</surname> <given-names>S.</given-names></name> <name><surname>Koike</surname> <given-names>M.</given-names></name> <name><surname>Taruno</surname> <given-names>Y.</given-names></name> <name><surname>Saiki</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2013b</year>). <article-title>ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons</article-title>. <source>FEBS Lett.</source> <volume>587</volume>, <fpage>1316</fpage>&#x02013;<lpage>1325</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2013.02.046</pub-id><pub-id pub-id-type="pmid">23499937</pub-id></citation></ref>
<ref id="B104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname> <given-names>H.</given-names></name> <name><surname>Uemura</surname> <given-names>N.</given-names></name> <name><surname>Yamakado</surname> <given-names>H.</given-names></name> <name><surname>Takeda</surname> <given-names>S.</given-names></name> <name><surname>Takahashi</surname> <given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Exploring the pathogenetic mechanisms underlying Parkinson&#x02019;s disease in medaka fish</article-title>. <source>J. Parkinsons Dis.</source> <volume>4</volume>, <fpage>301</fpage>&#x02013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.3233/JPD-130289</pub-id><pub-id pub-id-type="pmid">24366926</pub-id></citation></ref>
<ref id="B105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maulik</surname> <given-names>M.</given-names></name> <name><surname>Mitra</surname> <given-names>S.</given-names></name> <name><surname>Bult-Ito</surname> <given-names>A.</given-names></name> <name><surname>Taylor</surname> <given-names>B. E.</given-names></name> <name><surname>Vayndorf</surname> <given-names>E. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Behavioral phenotyping and pathological indicators of Parkinson&#x02019;s disease in <italic>C. elegans</italic> models</article-title>. <source>Front. Genet.</source> <volume>8</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2017.00077</pub-id><pub-id pub-id-type="pmid">28659967</pub-id></citation></ref>
<ref id="B106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGregor</surname> <given-names>M. M.</given-names></name> <name><surname>Nelson</surname> <given-names>A. B.</given-names></name></person-group> (<year>2019</year>). <article-title>Circuit mechanisms of Parkinson&#x02019;s disease</article-title>. <source>Neuron</source> <volume>101</volume>, <fpage>1042</fpage>&#x02013;<lpage>1056</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2019.03.004</pub-id><pub-id pub-id-type="pmid">30897356</pub-id></citation></ref>
<ref id="B107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGurk</surname> <given-names>L.</given-names></name> <name><surname>Berson</surname> <given-names>A.</given-names></name> <name><surname>Bonini</surname> <given-names>N. M.</given-names></name></person-group> (<year>2015</year>). <article-title><italic>Drosophila</italic> as an <italic>in vivo</italic> model for human neurodegenerative disease</article-title>. <source>Genetics</source> <volume>201</volume>, <fpage>377</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1534/genetics.115.179457</pub-id><pub-id pub-id-type="pmid">26447127</pub-id></citation></ref>
<ref id="B108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menezes</surname> <given-names>R.</given-names></name> <name><surname>Tenreiro</surname> <given-names>S.</given-names></name> <name><surname>Macedo</surname> <given-names>D.</given-names></name> <name><surname>Santos</surname> <given-names>C. N.</given-names></name> <name><surname>Outeiro</surname> <given-names>T. F.</given-names></name></person-group> (<year>2015</year>). <article-title>From the baker to the bedside: yeast models of Parkinson&#x02019;s disease</article-title>. <source>Microb. Cell</source> <volume>2</volume>, <fpage>262</fpage>&#x02013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.15698/mic2015.08.219</pub-id><pub-id pub-id-type="pmid">28357302</pub-id></citation></ref>
<ref id="B109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mikkelsen</surname> <given-names>M.</given-names></name> <name><surname>M&#x000F8;ller</surname> <given-names>A.</given-names></name> <name><surname>Jensen</surname> <given-names>L. H.</given-names></name> <name><surname>Pedersen</surname> <given-names>A.</given-names></name> <name><surname>Harajehi</surname> <given-names>J. B.</given-names></name> <name><surname>Pakkenberg</surname> <given-names>H.</given-names></name></person-group> (<year>1999</year>). <article-title>MPTP-induced Parkinsonism in minipigs: a behavioral, biochemical and histological study</article-title>. <source>Neurotoxicol. Teratol.</source> <volume>21</volume>, <fpage>169</fpage>&#x02013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/s0892-0362(98)00037-3</pub-id><pub-id pub-id-type="pmid">10192277</pub-id></citation></ref>
<ref id="B110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milanese</surname> <given-names>C.</given-names></name> <name><surname>Sager</surname> <given-names>J. J.</given-names></name> <name><surname>Bai</surname> <given-names>Q.</given-names></name> <name><surname>Farrell</surname> <given-names>T. C.</given-names></name> <name><surname>Cannon</surname> <given-names>J. R.</given-names></name> <name><surname>Greenamyre</surname> <given-names>J. T.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Hypokinesia and reduced dopamine levels in zebrafish lacking &#x003B2;- and &#x003B3;1-synucleins</article-title>. <source>J. Biol. Chem.</source> <volume>287</volume>, <fpage>2971</fpage>&#x02013;<lpage>2983</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.308312</pub-id><pub-id pub-id-type="pmid">22128150</pub-id></citation></ref>
<ref id="B111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morissette</surname> <given-names>M.</given-names></name> <name><surname>Di Paolo</surname> <given-names>T.</given-names></name></person-group> (<year>2018</year>). <article-title>Non-human primate models of PD to test novel therapies</article-title>. <source>J. Neural Transm.</source> <volume>125</volume>, <fpage>291</fpage>&#x02013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-017-1722-y</pub-id><pub-id pub-id-type="pmid">28391443</pub-id></citation></ref>
<ref id="B112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mortimer</surname> <given-names>R. K.</given-names></name></person-group> (<year>2000</year>). <article-title>Evolution and variation of the yeast (Saccharomyces) genome</article-title>. <source>Genome Res.</source> <volume>10</volume>, <fpage>403</fpage>&#x02013;<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1101/gr.10.4.403</pub-id><pub-id pub-id-type="pmid">10779481</pub-id></citation></ref>
<ref id="B113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nass</surname> <given-names>R.</given-names></name> <name><surname>Hall</surname> <given-names>D. H.</given-names></name> <name><surname>Miller</surname> <given-names>D. M.</given-names> <suffix>III.</suffix></name> <name><surname>Blakely</surname> <given-names>R. D.</given-names></name></person-group> (<year>2002</year>). <article-title>Neurotoxin-induced degeneration of dopamine neurons in <italic>Caenorhabditis elegans</italic></article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>99</volume>, <fpage>3264</fpage>&#x02013;<lpage>3269</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.042497999</pub-id><pub-id pub-id-type="pmid">11867711</pub-id></citation></ref>
<ref id="B114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nevzglyadova</surname> <given-names>O. V.</given-names></name> <name><surname>Mikhailova</surname> <given-names>E. V.</given-names></name> <name><surname>Artemov</surname> <given-names>A. V.</given-names></name> <name><surname>Ozerova</surname> <given-names>Y. E.</given-names></name> <name><surname>Ivanova</surname> <given-names>P. A.</given-names></name> <name><surname>Golomidov</surname> <given-names>I. M.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Yeast red pigment modifies cloned human &#x003B1;-synuclein pathogenesis in Parkinson disease models in <italic>Saccharomyces cerevisiae</italic> and <italic>Drosophila melanogaster</italic></article-title>. <source>Neurochem. Int.</source> <volume>120</volume>, <fpage>172</fpage>&#x02013;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2018.08.002</pub-id><pub-id pub-id-type="pmid">30099122</pub-id></citation></ref>
<ref id="B115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname> <given-names>M. S.</given-names></name> <name><surname>Glud</surname> <given-names>A. N.</given-names></name> <name><surname>M&#x000F8;ller</surname> <given-names>A.</given-names></name> <name><surname>Mogensen</surname> <given-names>P.</given-names></name> <name><surname>Bender</surname> <given-names>D.</given-names></name> <name><surname>S&#x000F8;rensen</surname> <given-names>J. C.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Continuous MPTP intoxication in the G&#x000F6;ttingen minipig results in chronic parkinsonian deficits</article-title>. <source>Acta Neurobiol. Exp.</source> <volume>76</volume>, <fpage>199</fpage>&#x02013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.21307/ane-2017-020</pub-id><pub-id pub-id-type="pmid">27685773</pub-id></citation></ref>
<ref id="B116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname> <given-names>M. S.</given-names></name> <name><surname>S&#x000F8;rensen</surname> <given-names>J. C.</given-names></name> <name><surname>Bjarkam</surname> <given-names>C. R.</given-names></name></person-group> (<year>2009</year>). <article-title>The substantia nigra pars compacta of the G&#x000F6;ttingen minipig: an anatomical and stereological study</article-title>. <source>Brain Struct. Funct.</source> <volume>213</volume>, <fpage>481</fpage>&#x02013;<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1007/s00429-009-0217-5</pub-id><pub-id pub-id-type="pmid">19705154</pub-id></citation></ref>
<ref id="B117"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Offenburger</surname> <given-names>S.-L.</given-names></name> <name><surname>Jongsma</surname> <given-names>E.</given-names></name> <name><surname>Gartner</surname> <given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Mutations in <italic>Caenorhabditis elegans</italic> neuroligin-like glit-1, the apoptosis pathway and the calcium chaperone crt-1 increase dopaminergic neurodegeneration after 6-OHDA treatment</article-title>. <source>PLoS Genet.</source> <volume>14</volume>:<fpage>e1007106</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1007106</pub-id><pub-id pub-id-type="pmid">29346364</pub-id></citation></ref>
<ref id="B118"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname> <given-names>A. L.</given-names></name> <name><surname>Feany</surname> <given-names>M. B.</given-names></name></person-group> (<year>2019</year>). <article-title>Glial &#x003B1;-synuclein promotes neurodegeneration characterized by a distinct transcriptional program <italic>in vivo</italic></article-title>. <source>Glia</source> <volume>67</volume>, <fpage>1933</fpage>&#x02013;<lpage>1957</lpage>. <pub-id pub-id-type="doi">10.1002/glia.23671</pub-id><pub-id pub-id-type="pmid">31267577</pub-id></citation></ref>
<ref id="B119"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orger</surname> <given-names>M. B.</given-names></name> <name><surname>de Polavieja</surname> <given-names>G. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Zebrafish behavior: opportunities and challenges</article-title>. <source>Annu. Rev. Neurosci.</source> <volume>40</volume>, <fpage>125</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-neuro-071714-033857</pub-id><pub-id pub-id-type="pmid">28375767</pub-id></citation></ref>
<ref id="B120"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Outeiro</surname> <given-names>T. F.</given-names></name> <name><surname>Lindquist</surname> <given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Yeast cells provide insight into &#x003B1;-synuclein biology and pathobiology</article-title>. <source>Science</source> <volume>302</volume>, <fpage>1772</fpage>&#x02013;<lpage>1775</lpage>. <pub-id pub-id-type="doi">10.1126/science.1090439</pub-id><pub-id pub-id-type="pmid">14657500</pub-id></citation></ref>
<ref id="B121"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>J.</given-names></name> <name><surname>Lee</surname> <given-names>S. B.</given-names></name> <name><surname>Lee</surname> <given-names>S.</given-names></name> <name><surname>Kim</surname> <given-names>Y.</given-names></name> <name><surname>Song</surname> <given-names>S.</given-names></name> <name><surname>Kim</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>Mitochondrial dysfunction in <italic>Drosophila</italic> PINK1 mutants is complemented by parkin</article-title>. <source>Nature</source> <volume>441</volume>, <fpage>1157</fpage>&#x02013;<lpage>1161</lpage>. <pub-id pub-id-type="doi">10.1038/nature04788</pub-id><pub-id pub-id-type="pmid">16672980</pub-id></citation></ref>
<ref id="B122"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname> <given-names>C.</given-names></name> <name><surname>Miguel Martins</surname> <given-names>L.</given-names></name> <name><surname>Saraiva</surname> <given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>LRRK2, but not pathogenic mutants, protects against H2O2 stress depending on mitochondrial function and endocytosis in a yeast model</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1840</volume>, <fpage>2025</fpage>&#x02013;<lpage>2031</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2014.02.015</pub-id><pub-id pub-id-type="pmid">24576675</pub-id></citation></ref>
<ref id="B123"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pesah</surname> <given-names>Y.</given-names></name> <name><surname>Pham</surname> <given-names>T.</given-names></name> <name><surname>Burgess</surname> <given-names>H.</given-names></name> <name><surname>Middlebrooks</surname> <given-names>B.</given-names></name> <name><surname>Verstreken</surname> <given-names>P.</given-names></name> <name><surname>Zhou</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title><italic>Drosophila</italic> parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress</article-title>. <source>Development</source> <volume>131</volume>, <fpage>2183</fpage>&#x02013;<lpage>2194</lpage>. <pub-id pub-id-type="doi">10.1242/dev.01095</pub-id><pub-id pub-id-type="pmid">15073152</pub-id></citation></ref>
<ref id="B124"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pignataro</surname> <given-names>D.</given-names></name> <name><surname>Sucunza</surname> <given-names>D.</given-names></name> <name><surname>Rico</surname> <given-names>A. J.</given-names></name> <name><surname>Dopeso-Reyes</surname> <given-names>I. G.</given-names></name> <name><surname>Roda</surname> <given-names>E.</given-names></name> <name><surname>Rodr&#x000ED;guez-Perez</surname> <given-names>A. I.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Gene therapy approaches in the non-human primate model of Parkinson&#x02019;s disease</article-title>. <source>J. Neural Transm.</source> <volume>125</volume>, <fpage>575</fpage>&#x02013;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-017-1681-3</pub-id><pub-id pub-id-type="pmid">28130586</pub-id></citation></ref>
<ref id="B125"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinho</surname> <given-names>B. R.</given-names></name> <name><surname>Reis</surname> <given-names>S. D.</given-names></name> <name><surname>Guedes-Dias</surname> <given-names>P.</given-names></name> <name><surname>Leit&#x000E3;o-Rocha</surname> <given-names>A.</given-names></name> <name><surname>Quintas</surname> <given-names>C.</given-names></name> <name><surname>Valent&#x000E3;o</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Pharmacological modulation of HDAC1 and HDAC6 <italic>in vivo</italic> in a zebrafish model: therapeutic implications for Parkinson&#x02019;s disease</article-title>. <source>Pharmacol. Res.</source> <volume>103</volume>, <fpage>328</fpage>&#x02013;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2015.11.024</pub-id><pub-id pub-id-type="pmid">26657418</pub-id></citation></ref>
<ref id="B126"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitchai</surname> <given-names>A.</given-names></name> <name><surname>Rajaretinam</surname> <given-names>R. K.</given-names></name> <name><surname>Freeman</surname> <given-names>J. L.</given-names></name></person-group> (<year>2019</year>). <article-title>Zebrafish as an emerging model for bioassay-guided natural product drug discovery for neurological disorders</article-title>. <source>Medicines</source> <volume>6</volume>:<fpage>61</fpage>. <pub-id pub-id-type="doi">10.3390/medicines6020061</pub-id><pub-id pub-id-type="pmid">31151179</pub-id></citation></ref>
<ref id="B127"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polymeropoulos</surname> <given-names>M. H.</given-names></name> <name><surname>Hurko</surname> <given-names>O.</given-names></name> <name><surname>Hsu</surname> <given-names>F.</given-names></name> <name><surname>Rubenstein</surname> <given-names>J.</given-names></name> <name><surname>Basnet</surname> <given-names>S.</given-names></name> <name><surname>Lane</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>1997</year>). <article-title>Linkage of the locus for cerebral cavernous hemangiomas to human chromosome 7q in four families of Mexican-American descent</article-title>. <source>Neurology</source> <volume>48</volume>, <fpage>752</fpage>&#x02013;<lpage>757</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.48.3.752</pub-id><pub-id pub-id-type="pmid">9065560</pub-id></citation></ref>
<ref id="B128"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Postuma</surname> <given-names>R. B.</given-names></name> <name><surname>Gagnon</surname> <given-names>J.-F.</given-names></name> <name><surname>Bertrand</surname> <given-names>J.-A.</given-names></name> <name><surname>Genier Marchand</surname> <given-names>D.</given-names></name> <name><surname>Montplaisir</surname> <given-names>J. Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials</article-title>. <source>Neurology</source> <volume>84</volume>, <fpage>1104</fpage>&#x02013;<lpage>1113</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000001364</pub-id><pub-id pub-id-type="pmid">25681454</pub-id></citation></ref>
<ref id="B129"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prabhudesai</surname> <given-names>S.</given-names></name> <name><surname>Bensabeur</surname> <given-names>F. Z.</given-names></name> <name><surname>Abdullah</surname> <given-names>R.</given-names></name> <name><surname>Basak</surname> <given-names>I.</given-names></name> <name><surname>Baez</surname> <given-names>S.</given-names></name> <name><surname>Alves</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation</article-title>. <source>J. Neurosci. Res.</source> <volume>94</volume>, <fpage>717</fpage>&#x02013;<lpage>735</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.23754</pub-id><pub-id pub-id-type="pmid">27265751</pub-id></citation></ref>
<ref id="B130"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prabhudesai</surname> <given-names>S.</given-names></name> <name><surname>Sinha</surname> <given-names>S.</given-names></name> <name><surname>Attar</surname> <given-names>A.</given-names></name> <name><surname>Kotagiri</surname> <given-names>A.</given-names></name> <name><surname>Fitzmaurice</surname> <given-names>A. G.</given-names></name> <name><surname>Lakshmanan</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>A novel &#x0201C;molecular tweezer&#x0201D; inhibitor of &#x003B1;-synuclein neurotoxicity <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Neurotherapeutics</source> <volume>9</volume>, <fpage>464</fpage>&#x02013;<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-012-0105-1</pub-id><pub-id pub-id-type="pmid">22373667</pub-id></citation></ref>
<ref id="B131"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramot</surname> <given-names>Y.</given-names></name> <name><surname>Nyska</surname> <given-names>A.</given-names></name> <name><surname>Maronpot</surname> <given-names>R. R.</given-names></name> <name><surname>Shaltiel-Karyo</surname> <given-names>R.</given-names></name> <name><surname>Tsarfati</surname> <given-names>Y.</given-names></name> <name><surname>Manno</surname> <given-names>R. A.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Ninety-day local tolerability and toxicity Study of ND0612, a novel formulation of levodopa/carbidopa, administered by subcutaneous continuous infusion in minipigs</article-title>. <source>Toxicol. Pathol.</source> <volume>45</volume>, <fpage>764</fpage>&#x02013;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1177/0192623317729891</pub-id><pub-id pub-id-type="pmid">28891435</pub-id></citation></ref>
<ref id="B132"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname> <given-names>C.</given-names></name> <name><surname>Hu</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Zhou</surname> <given-names>Q.</given-names></name></person-group> (<year>2016</year>). <article-title>Ultra-trace graphene oxide in a water environment triggers Parkinson&#x02019;s disease-like symptoms and metabolic disturbance in zebrafish larvae</article-title>. <source>Biomaterials</source> <volume>93</volume>, <fpage>83</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.03.036</pub-id><pub-id pub-id-type="pmid">27085073</pub-id></citation></ref>
<ref id="B133"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenblad</surname> <given-names>C.</given-names></name> <name><surname>Li</surname> <given-names>Q.</given-names></name> <name><surname>Pioli</surname> <given-names>E. Y.</given-names></name> <name><surname>Dovero</surname> <given-names>S.</given-names></name> <name><surname>Antunes</surname> <given-names>A. S.</given-names></name> <name><surname>Ag&#x000FA;ndez</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson&#x02019;s disease</article-title>. <source>Brain</source> <volume>142</volume>, <fpage>2402</fpage>&#x02013;<lpage>2416</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awz176</pub-id><pub-id pub-id-type="pmid">31243443</pub-id></citation></ref>
<ref id="B134"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname> <given-names>Q.</given-names></name> <name><surname>Harrington</surname> <given-names>A. J.</given-names></name> <name><surname>Caldwell</surname> <given-names>K. A.</given-names></name> <name><surname>Caldwell</surname> <given-names>G. A.</given-names></name> <name><surname>Standaert</surname> <given-names>D. G.</given-names></name></person-group> (<year>2010</year>). <article-title>VPS41, a protein involved in lysosomal trafficking, is protective in <italic>Caenorhabditis elegans</italic> and mammalian cellular models of Parkinson&#x02019;s disease</article-title>. <source>Neurobiol. Dis.</source> <volume>37</volume>, <fpage>330</fpage>&#x02013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2009.10.011</pub-id><pub-id pub-id-type="pmid">19850127</pub-id></citation></ref>
<ref id="B135"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruotolo</surname> <given-names>R.</given-names></name> <name><surname>De Giorgio</surname> <given-names>G.</given-names></name> <name><surname>Minato</surname> <given-names>I.</given-names></name> <name><surname>Bianchi</surname> <given-names>M. G.</given-names></name> <name><surname>Bussolati</surname> <given-names>O.</given-names></name> <name><surname>Marmiroli</surname> <given-names>N.</given-names></name></person-group> (<year>2020</year>). <article-title>Cerium oxide nanoparticles rescue &#x003B1;-synuclein-induced toxicity in a yeast model of Parkinson&#x02019;s disease</article-title>. <source>Nanomaterials</source> <volume>10</volume>:<fpage>235</fpage>. <pub-id pub-id-type="doi">10.3390/nano10020235</pub-id><pub-id pub-id-type="pmid">32013138</pub-id></citation></ref>
<ref id="B136"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sammi</surname> <given-names>S. R.</given-names></name> <name><surname>Agim</surname> <given-names>Z. S.</given-names></name> <name><surname>Cannon</surname> <given-names>J. R.</given-names></name></person-group> (<year>2018</year>). <article-title>From the cover: harmane-induced selective dopaminergic neurotoxicity in <italic>Caenorhabditis elegans</italic></article-title>. <source>Toxicol. Sci.</source> <volume>161</volume>, <fpage>335</fpage>&#x02013;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfx223</pub-id><pub-id pub-id-type="pmid">29069497</pub-id></citation></ref>
<ref id="B137"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x000E1;nchez-Ferro</surname> <given-names>A.</given-names></name> <name><surname>R&#x000E1;bano</surname> <given-names>A.</given-names></name> <name><surname>Catal&#x000E1;n</surname> <given-names>M. J.</given-names></name> <name><surname>Rodr&#x000ED;guez-Valc&#x000E1;rcel</surname> <given-names>F. C.</given-names></name> <name><surname>Fern&#x000E1;ndez D&#x000ED;ez</surname> <given-names>S.</given-names></name> <name><surname>Herreros-Rodr&#x000ED;guez</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title><italic>In vivo</italic> gastric detection of &#x003B1;-synuclein inclusions in Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>30</volume>, <fpage>517</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1002/mds.25988</pub-id><pub-id pub-id-type="pmid">25113060</pub-id></citation></ref>
<ref id="B138"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarath Babu</surname> <given-names>N.</given-names></name> <name><surname>Murthy Ch</surname> <given-names>L.</given-names></name> <name><surname>Kakara</surname> <given-names>S.</given-names></name> <name><surname>Sharma</surname> <given-names>R.</given-names></name> <name><surname>Brahmendra Swamy</surname> <given-names>C. V.</given-names></name> <name><surname>Idris</surname> <given-names>M. M.</given-names></name></person-group> (<year>2016</year>). <article-title>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson&#x02019;s disease in zebrafish</article-title>. <source>Proteomics</source> <volume>16</volume>, <fpage>1407</fpage>&#x02013;<lpage>1420</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.201500291</pub-id><pub-id pub-id-type="pmid">26959078</pub-id></citation></ref>
<ref id="B139"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Savica</surname> <given-names>R.</given-names></name> <name><surname>Rocca</surname> <given-names>W. A.</given-names></name> <name><surname>Ahlskog</surname> <given-names>J. E.</given-names></name></person-group> (<year>2010</year>). <article-title>When does Parkinson disease start?</article-title> <source>Arch. Neurol.</source> <volume>67</volume>, <fpage>798</fpage>&#x02013;<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1001/archneurol.2010.135</pub-id><pub-id pub-id-type="pmid">20625084</pub-id></citation></ref>
<ref id="B140"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seegobin</surname> <given-names>S. P.</given-names></name> <name><surname>Heaton</surname> <given-names>G. R.</given-names></name> <name><surname>Liang</surname> <given-names>D.</given-names></name> <name><surname>Choi</surname> <given-names>I.</given-names></name> <name><surname>Blanca Ramirez</surname> <given-names>M.</given-names></name> <name><surname>Tang</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Progress in <italic>LRRK2</italic>-associated Parkinson&#x02019;s disease animal models</article-title>. <source>Front. Neurosci.</source> <volume>14</volume>:<fpage>674</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2020.00674</pub-id><pub-id pub-id-type="pmid">32765209</pub-id></citation></ref>
<ref id="B141"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname> <given-names>J.</given-names></name> <name><surname>Lee</surname> <given-names>Y.</given-names></name> <name><surname>Kim</surname> <given-names>B. S.</given-names></name> <name><surname>Park</surname> <given-names>J.</given-names></name> <name><surname>Yang</surname> <given-names>S.</given-names></name> <name><surname>Yoon</surname> <given-names>H. J.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>A non-human primate model for stable chronic Parkinson&#x02019;s disease induced by MPTP administration based on individual behavioral quantification</article-title>. <source>J. Neurosci. Methods</source> <volume>311</volume>, <fpage>277</fpage>&#x02013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2018.10.037</pub-id><pub-id pub-id-type="pmid">30391524</pub-id></citation></ref>
<ref id="B142"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sgambato</surname> <given-names>V.</given-names></name> <name><surname>Tremblay</surname> <given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers</article-title>. <source>J. Neural Transm.</source> <volume>125</volume>, <fpage>1145</fpage>&#x02013;<lpage>1156</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-018-1871-7</pub-id><pub-id pub-id-type="pmid">29502255</pub-id></citation></ref>
<ref id="B143"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimozawa</surname> <given-names>A.</given-names></name> <name><surname>Ono</surname> <given-names>M.</given-names></name> <name><surname>Takahara</surname> <given-names>D.</given-names></name> <name><surname>Tarutani</surname> <given-names>A.</given-names></name> <name><surname>Imura</surname> <given-names>S.</given-names></name> <name><surname>Masuda-Suzukake</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Propagation of pathological &#x003B1;-synuclein in marmoset brain</article-title>. <source>Acta Neuropathol. Commun.</source> <volume>5</volume>:<fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/s40478-017-0413-0</pub-id><pub-id pub-id-type="pmid">28148299</pub-id></citation></ref>
<ref id="B144"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname> <given-names>J. M.</given-names></name> <name><surname>Shulman</surname> <given-names>L. M.</given-names></name> <name><surname>Weiner</surname> <given-names>W. J.</given-names></name> <name><surname>Feany</surname> <given-names>M. B.</given-names></name></person-group> (<year>2003</year>). <article-title>From fruit fly to bedside: translating lessons from <italic>Drosophila</italic> models of neurodegenerative disease</article-title>. <source>Curr. Opin. Neurol.</source> <volume>16</volume>, <fpage>443</fpage>&#x02013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1097/01.wco.0000084220.82329.60</pub-id><pub-id pub-id-type="pmid">12869801</pub-id></citation></ref>
<ref id="B145"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soman</surname> <given-names>S. K.</given-names></name> <name><surname>Baza&#x00142;a</surname> <given-names>M.</given-names></name> <name><surname>Keatinge</surname> <given-names>M.</given-names></name> <name><surname>Bandmann</surname> <given-names>O.</given-names></name> <name><surname>Kuznicki</surname> <given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Restriction of mitochondrial calcium overload by <italic>mcu</italic> inactivation renders a neuroprotective effect in zebrafish models of Parkinson&#x02019;s disease</article-title>. <source>Biol. Open</source> <volume>8</volume>:<fpage>bio044347</fpage>. <pub-id pub-id-type="doi">10.1242/bio.044347</pub-id><pub-id pub-id-type="pmid">31548178</pub-id></citation></ref>
<ref id="B146"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soper</surname> <given-names>J. H.</given-names></name> <name><surname>Roy</surname> <given-names>S.</given-names></name> <name><surname>Stieber</surname> <given-names>A.</given-names></name> <name><surname>Lee</surname> <given-names>E.</given-names></name> <name><surname>Wilson</surname> <given-names>R. B.</given-names></name> <name><surname>Trojanowski</surname> <given-names>J. Q.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>&#x003B1;-synuclein-induced aggregation of cytoplasmic vesicles in <italic>Saccharomyces cerevisiae</italic></article-title>. <source>Mol. Biol. Cell</source> <volume>19</volume>, <fpage>1093</fpage>&#x02013;<lpage>1103</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.e07-08-0827</pub-id><pub-id pub-id-type="pmid">18172022</pub-id></citation></ref>
<ref id="B147"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sousa e Silva</surname> <given-names>J. P.</given-names></name> <name><surname>Lobo</surname> <given-names>J. S.</given-names></name> <name><surname>Bonif&#x000E1;cio</surname> <given-names>M. J.</given-names></name> <name><surname>Machado</surname> <given-names>R.</given-names></name> <name><surname>Falc&#x000E3;o</surname> <given-names>A.</given-names></name> <name><surname>Soares-da-Silva</surname> <given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title><italic>In vivo</italic> evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in G&#x000F6;ttingen minipigs</article-title>. <source>J. Pharm. Pharmacol.</source> <volume>63</volume>, <fpage>780</fpage>&#x02013;<lpage>785</lpage>. <pub-id pub-id-type="doi">10.1111/j.2042-7158.2011.01278.x</pub-id><pub-id pub-id-type="pmid">21585375</pub-id></citation></ref>
<ref id="B148"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stednitz</surname> <given-names>S. J.</given-names></name> <name><surname>Freshner</surname> <given-names>B.</given-names></name> <name><surname>Shelton</surname> <given-names>S.</given-names></name> <name><surname>Shen</surname> <given-names>T.</given-names></name> <name><surname>Black</surname> <given-names>D.</given-names></name> <name><surname>Gahtan</surname> <given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Selective toxicity of L-DOPA to dopamine transporter-expressing neurons and locomotor behavior in zebrafish larvae</article-title>. <source>Neurotoxicol. Teratol.</source> <volume>52</volume>, <fpage>51</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.ntt.2015.11.001</pub-id><pub-id pub-id-type="pmid">26546233</pub-id></citation></ref>
<ref id="B149"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname> <given-names>J. W.</given-names></name> <name><surname>Ju</surname> <given-names>S.</given-names></name> <name><surname>Lachenmayer</surname> <given-names>M. L.</given-names></name> <name><surname>Liken</surname> <given-names>J.</given-names></name> <name><surname>Stock</surname> <given-names>A.</given-names></name> <name><surname>Kim</surname> <given-names>S. H.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Latrepirdine stimulates autophagy and reduces accumulation of &#x003B1;-synuclein in cells and in mouse brain</article-title>. <source>Mol. Psychiatry</source> <volume>18</volume>, <fpage>882</fpage>&#x02013;<lpage>888</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2012.115</pub-id><pub-id pub-id-type="pmid">22869031</pub-id></citation></ref>
<ref id="B150"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>L. J.</given-names></name> <name><surname>Auluck</surname> <given-names>P. K.</given-names></name> <name><surname>Outeiro</surname> <given-names>T. F.</given-names></name> <name><surname>Yeger-Lotem</surname> <given-names>E.</given-names></name> <name><surname>Kritzer</surname> <given-names>J. A.</given-names></name> <name><surname>Tardiff</surname> <given-names>D. F.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson&#x02019;s disease models</article-title>. <source>Dis. Model Mech.</source> <volume>3</volume>, <fpage>194</fpage>&#x02013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.004267</pub-id><pub-id pub-id-type="pmid">20038714</pub-id></citation></ref>
<ref id="B151"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sundberg</surname> <given-names>M.</given-names></name> <name><surname>Bogetofte</surname> <given-names>H.</given-names></name> <name><surname>Lawson</surname> <given-names>T.</given-names></name> <name><surname>Jansson</surname> <given-names>J.</given-names></name> <name><surname>Smith</surname> <given-names>G.</given-names></name> <name><surname>Astradsson</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Improved cell therapy protocols for Parkinson&#x02019;s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons</article-title>. <source>Stem Cells</source> <volume>31</volume>, <fpage>1548</fpage>&#x02013;<lpage>1562</lpage>. <pub-id pub-id-type="doi">10.1002/stem.1415</pub-id><pub-id pub-id-type="pmid">23666606</pub-id></citation></ref>
<ref id="B152"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarakad</surname> <given-names>A.</given-names></name> <name><surname>Jankovic</surname> <given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Diagnosis and management of Parkinson&#x02019;s disease</article-title>. <source>Semin. Neurol.</source> <volume>37</volume>, <fpage>118</fpage>&#x02013;<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1055/s-0037-1601888</pub-id><pub-id pub-id-type="pmid">28511252</pub-id></citation></ref>
<ref id="B153"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tardiff</surname> <given-names>D. F.</given-names></name> <name><surname>Jui</surname> <given-names>N. T.</given-names></name> <name><surname>Khurana</surname> <given-names>V.</given-names></name> <name><surname>Tambe</surname> <given-names>M. A.</given-names></name> <name><surname>Thompson</surname> <given-names>M. L.</given-names></name> <name><surname>Chung</surname> <given-names>C. Y.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Yeast reveal a &#x0201C;druggable&#x0201D; Rsp5/Nedd4 network that ameliorates &#x003B1;-synuclein toxicity in neurons</article-title>. <source>Science</source> <volume>342</volume>, <fpage>979</fpage>&#x02013;<lpage>983</lpage>. <pub-id pub-id-type="doi">10.1126/science.1245321</pub-id><pub-id pub-id-type="pmid">24158909</pub-id></citation></ref>
<ref id="B154"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teil</surname> <given-names>M.</given-names></name> <name><surname>Arotcarena</surname> <given-names>M. L.</given-names></name> <name><surname>Faggiani</surname> <given-names>E.</given-names></name> <name><surname>Laferriere</surname> <given-names>F.</given-names></name> <name><surname>Bezard</surname> <given-names>E.</given-names></name> <name><surname>Dehay</surname> <given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Targeting &#x003B1;-synuclein for PD therapeutics: a pursuit on all fronts</article-title>. <source>Biomolecules</source> <volume>10</volume>:<fpage>391</fpage>. <pub-id pub-id-type="doi">10.3390/biom10030391</pub-id><pub-id pub-id-type="pmid">32138193</pub-id></citation></ref>
<ref id="B155"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tenreiro</surname> <given-names>S.</given-names></name> <name><surname>Outeiro</surname> <given-names>T. F.</given-names></name></person-group> (<year>2010</year>). <article-title>Simple is good: yeast models of neurodegeneration</article-title>. <source>FEMS Yeast Res.</source> <volume>10</volume>, <fpage>970</fpage>&#x02013;<lpage>979</lpage>. <pub-id pub-id-type="doi">10.1111/j.1567-1364.2010.00649.x</pub-id><pub-id pub-id-type="pmid">20579105</pub-id></citation></ref>
<ref id="B156"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>&#x000DC;nal</surname> <given-names>&#x00130;.</given-names></name> <name><surname>&#x000C7;al&#x00131;&#x0015F;kan-Ak</surname> <given-names>E.</given-names></name> <name><surname>&#x000DC;st&#x000FC;nda&#x0011F;</surname> <given-names>V.</given-names></name> <name><surname>Ate&#x0015F;</surname> <given-names>P. S.</given-names></name> <name><surname>Alturfan</surname> <given-names>A. A.</given-names></name> <name><surname>Altinoz</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Neuroprotective effects of mitoquinone and oleandrin on Parkinson&#x02019;s disease model in zebrafish</article-title>. <source>Int. J. Neurosci.</source> <volume>130</volume>, <fpage>574</fpage>&#x02013;<lpage>582</lpage>. <pub-id pub-id-type="doi">10.1080/00207454.2019.1698567</pub-id><pub-id pub-id-type="pmid">31771386</pub-id></citation></ref>
<ref id="B157"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaz</surname> <given-names>R. L.</given-names></name> <name><surname>Outeiro</surname> <given-names>T. F.</given-names></name> <name><surname>Ferreira</surname> <given-names>J. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Zebrafish as an animal model for drug discovery in Parkinson&#x02019;s disease and other movement disorders: a systematic review</article-title>. <source>Front. Neurol.</source> <volume>9</volume>:<fpage>347</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2018.00347</pub-id><pub-id pub-id-type="pmid">29910763</pub-id></citation></ref>
<ref id="B158"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venderova</surname> <given-names>K.</given-names></name> <name><surname>Kabbach</surname> <given-names>G.</given-names></name> <name><surname>Abdel-Messih</surname> <given-names>E.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Parks</surname> <given-names>R. J.</given-names></name> <name><surname>Imai</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a <italic>Drosophila melanogaster</italic> model of Parkinson&#x02019;s disease</article-title>. <source>Hum. Mol. Genet.</source> <volume>18</volume>, <fpage>4390</fpage>&#x02013;<lpage>4404</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddp394</pub-id><pub-id pub-id-type="pmid">19692353</pub-id></citation></ref>
<ref id="B159"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verhave</surname> <given-names>P. S.</given-names></name> <name><surname>Jongsma</surname> <given-names>M. J.</given-names></name> <name><surname>Van den Berg</surname> <given-names>R. M.</given-names></name> <name><surname>Vis</surname> <given-names>J. C.</given-names></name> <name><surname>Vanwersch</surname> <given-names>R. A.</given-names></name> <name><surname>Smit</surname> <given-names>A. B.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease</article-title>. <source>Sleep</source> <volume>34</volume>, <fpage>1119</fpage>&#x02013;<lpage>1125</lpage>. <pub-id pub-id-type="doi">10.5665/SLEEP.1174</pub-id><pub-id pub-id-type="pmid">21804674</pub-id></citation></ref>
<ref id="B160"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vezoli</surname> <given-names>J.</given-names></name> <name><surname>Dzahini</surname> <given-names>K.</given-names></name> <name><surname>Costes</surname> <given-names>N.</given-names></name> <name><surname>Wilson</surname> <given-names>C. R.</given-names></name> <name><surname>Fifel</surname> <given-names>K.</given-names></name> <name><surname>Cooper</surname> <given-names>H. M.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Increased DAT binding in the early stage of the dopaminergic lesion: a longitudinal [11C]PE2I binding study in the MPTP-monkey</article-title>. <source>NeuroImage</source> <volume>102</volume>, <fpage>249</fpage>&#x02013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2014.07.059</pub-id><pub-id pub-id-type="pmid">25108180</pub-id></citation></ref>
<ref id="B161"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilari&#x000F1;o-G&#x000FC;ell</surname> <given-names>C.</given-names></name> <name><surname>Wider</surname> <given-names>C.</given-names></name> <name><surname>Ross</surname> <given-names>O. A.</given-names></name> <name><surname>Dachsel</surname> <given-names>J. C.</given-names></name> <name><surname>Kachergus</surname> <given-names>J. M.</given-names></name> <name><surname>Lincoln</surname> <given-names>S. J.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>VPS35 mutations in Parkinson disease</article-title>. <source>Am. J. Hum. Genet.</source> <volume>89</volume>, <fpage>162</fpage>&#x02013;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.001</pub-id><pub-id pub-id-type="pmid">21763482</pub-id></citation></ref>
<ref id="B162"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wakeman</surname> <given-names>D. R.</given-names></name> <name><surname>Crain</surname> <given-names>A. M.</given-names></name> <name><surname>Snyder</surname> <given-names>E. Y.</given-names></name></person-group> (<year>2006</year>). <article-title>Large animal models are critical for rationally advancing regenerative therapies</article-title>. <source>Regen. Med.</source> <volume>1</volume>, <fpage>405</fpage>&#x02013;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.2217/17460751.1.4.405</pub-id><pub-id pub-id-type="pmid">17465832</pub-id></citation></ref>
<ref id="B165"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Cao</surname> <given-names>C.</given-names></name> <name><surname>Huang</surname> <given-names>J.</given-names></name> <name><surname>Yao</surname> <given-names>J.</given-names></name> <name><surname>Hai</surname> <given-names>T.</given-names></name> <name><surname>Zheng</surname> <given-names>Q.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system</article-title>. <source>Sci. Rep.</source> <volume>6</volume>:<fpage>20620</fpage>. <pub-id pub-id-type="doi">10.1038/srep20620</pub-id><pub-id pub-id-type="pmid">26857844</pub-id></citation></ref>
<ref id="B166"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>W.</given-names></name> <name><surname>Yang</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>F.</given-names></name> <name><surname>Sima</surname> <given-names>Y.</given-names></name> <name><surname>Zhong</surname> <given-names>Z. M.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Parkinson&#x02019;s disease-like motor and non-motor symptoms in rotenone-treated zebrafish</article-title>. <source>Neurotoxicology</source> <volume>58</volume>, <fpage>103</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2016.11.006</pub-id><pub-id pub-id-type="pmid">27866991</pub-id></citation></ref>
<ref id="B164"><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>M.</given-names></name> <name><surname>Song</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>S.</given-names></name> <name><surname>Xu</surname> <given-names>S.</given-names></name> <name><surname>Xiao</surname> <given-names>G.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2018</year>). &#x0201C;<article-title>Abnormal spontaneous neuronal discharge and local field potential both in cortex and striatum of a non-human primate of Parkinson&#x02019;s disease using implantable microelectrode arrays</article-title>,&#x0201D; in <source>2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)</source> (<conf-loc>Honolulu, HI, USA</conf-loc>). <pub-id pub-id-type="doi">10.1109/EMBC.2018.8512999</pub-id><pub-id pub-id-type="pmid">30440282</pub-id></citation></ref>
<ref id="B163"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>G.</given-names></name> <name><surname>Zhang</surname> <given-names>G.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Fawcett</surname> <given-names>C. H.</given-names></name> <name><surname>Coble</surname> <given-names>M.</given-names></name> <name><surname>Sosa</surname> <given-names>M. X.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Abnormal behavior of zebrafish mutant in dopamine transporter is rescued by clozapine</article-title>. <source>iScience</source> <volume>17</volume>, <fpage>325</fpage>&#x02013;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2019.06.039</pub-id><pub-id pub-id-type="pmid">31325771</pub-id></citation></ref>
<ref id="B167"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wianny</surname> <given-names>F.</given-names></name> <name><surname>Vezoli</surname> <given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Transplantation in the nonhuman primate MPTP model of Parkinson&#x02019;s disease: update and perspectives</article-title>. <source>Primate Biol.</source> <volume>4</volume>, <fpage>185</fpage>&#x02013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.5194/pb-4-185-2017</pub-id><pub-id pub-id-type="pmid">32110706</pub-id></citation></ref>
<ref id="B168"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wichmann</surname> <given-names>T.</given-names></name> <name><surname>Bergman</surname> <given-names>H.</given-names></name> <name><surname>DeLong</surname> <given-names>M. R.</given-names></name></person-group> (<year>2018</year>). <article-title>Basal ganglia, movement disorders and deep brain stimulation: advances made through non-human primate research</article-title>. <source>J. Neural Transm.</source> <volume>125</volume>, <fpage>419</fpage>&#x02013;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-017-1736-5</pub-id><pub-id pub-id-type="pmid">28601961</pub-id></citation></ref>
<ref id="B169"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>R. B.</given-names></name> <name><surname>Gutekunst</surname> <given-names>W. R.</given-names></name> <name><surname>Joyner</surname> <given-names>P. M.</given-names></name> <name><surname>Duan</surname> <given-names>W.</given-names></name> <name><surname>Li</surname> <given-names>Q.</given-names></name> <name><surname>Ross</surname> <given-names>C. A.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Bioactivity profiling with parallel mass spectrometry reveals an assemblage of green tea metabolites affording protection against human huntingtin and &#x003B1;-synuclein toxicity</article-title>. <source>J. Agric. Food Chem.</source> <volume>55</volume>, <fpage>9450</fpage>&#x02013;<lpage>9456</lpage>. <pub-id pub-id-type="doi">10.1021/jf072241x</pub-id><pub-id pub-id-type="pmid">17944533</pub-id></citation></ref>
<ref id="B170"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willingham</surname> <given-names>S.</given-names></name> <name><surname>Outeiro</surname> <given-names>T. F.</given-names></name> <name><surname>DeVit</surname> <given-names>M. J.</given-names></name> <name><surname>Lindquist</surname> <given-names>S.-L.</given-names></name> <name><surname>Muchowski</surname> <given-names>P. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Yeast genes that enhance the toxicity of a mutant huntingtin fragment or &#x003B1;-synuclein</article-title>. <source>Science</source> <volume>302</volume>, <fpage>1769</fpage>&#x02013;<lpage>1772</lpage>. <pub-id pub-id-type="doi">10.1126/science.1090389</pub-id><pub-id pub-id-type="pmid">14657499</pub-id></citation></ref>
<ref id="B171"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>W&#x000F6;hlke</surname> <given-names>A.</given-names></name> <name><surname>Philipp</surname> <given-names>U.</given-names></name> <name><surname>Bock</surname> <given-names>P.</given-names></name> <name><surname>Beineke</surname> <given-names>A.</given-names></name> <name><surname>Lichtner</surname> <given-names>P.</given-names></name> <name><surname>Meitinger</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier</article-title>. <source>PLoS Genet.</source> <volume>7</volume>:<fpage>e1002304</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1002304</pub-id><pub-id pub-id-type="pmid">22022275</pub-id></citation></ref>
<ref id="B172"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolozin</surname> <given-names>B.</given-names></name> <name><surname>Gabel</surname> <given-names>C.</given-names></name> <name><surname>Ferree</surname> <given-names>A.</given-names></name> <name><surname>Guillily</surname> <given-names>M.</given-names></name> <name><surname>Ebata</surname> <given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Watching worms whither: modeling neurodegeneration in <italic>C. elegans</italic></article-title>. <source>Prog. Mol. Biol. Transl. Sci.</source> <volume>100</volume>, <fpage>499</fpage>&#x02013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-384878-9.00015-7</pub-id><pub-id pub-id-type="pmid">21377635</pub-id></citation></ref>
<ref id="B173"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname> <given-names>Y.</given-names></name> <name><surname>Coombes</surname> <given-names>C. E.</given-names></name> <name><surname>Kilaru</surname> <given-names>A.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Gitler</surname> <given-names>A. D.</given-names></name> <name><surname>Bowers</surname> <given-names>W. J.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>GTPase activity plays a key role in the pathobiology of LRRK2</article-title>. <source>PLoS Genet.</source> <volume>6</volume>:<fpage>e1000902</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1000902</pub-id><pub-id pub-id-type="pmid">20386743</pub-id></citation></ref>
<ref id="B174"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>D.</given-names></name> <name><surname>Zhao</surname> <given-names>D.</given-names></name> <name><surname>Ali Shah</surname> <given-names>S. Z.</given-names></name> <name><surname>Wu</surname> <given-names>W.</given-names></name> <name><surname>Lai</surname> <given-names>M.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>The role of the gut microbiota in the pathogenesis of Parkinson&#x02019;s disease</article-title>. <source>Front. Neurol.</source> <volume>10</volume>:<fpage>1155</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2019.01155</pub-id><pub-id pub-id-type="pmid">31781020</pub-id></citation></ref>
<ref id="B175"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y.</given-names></name> <name><surname>Gehrke</surname> <given-names>S.</given-names></name> <name><surname>Imai</surname> <given-names>Y.</given-names></name> <name><surname>Huang</surname> <given-names>Z.</given-names></name> <name><surname>Ouyang</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>J. W.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of <italic>Drosophila</italic> Pink1 is rescued by Parkin</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>103</volume>, <fpage>10793</fpage>&#x02013;<lpage>10798</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0602493103</pub-id><pub-id pub-id-type="pmid">16818890</pub-id></citation></ref>
<ref id="B176"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeger-Lotem</surname> <given-names>E.</given-names></name> <name><surname>Riva</surname> <given-names>L.</given-names></name> <name><surname>Su</surname> <given-names>L. J.</given-names></name> <name><surname>Gitler</surname> <given-names>A. D.</given-names></name> <name><surname>Cashikar</surname> <given-names>A. G.</given-names></name> <name><surname>King</surname> <given-names>O. D.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Bridging high-throughput genetic and transcriptional data reveals cellular responses to &#x003B1;-synuclein toxicity</article-title>. <source>Nat. Genet.</source> <volume>41</volume>, <fpage>316</fpage>&#x02013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1038/ng.337</pub-id><pub-id pub-id-type="pmid">19234470</pub-id></citation></ref>
<ref id="B177"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Youssef</surname> <given-names>K.</given-names></name> <name><surname>Tandon</surname> <given-names>A.</given-names></name> <name><surname>Rezai</surname> <given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>Studying Parkinson&#x02019;s disease using <italic>Caenorhabditis elegans</italic> models in microfluidic devices</article-title>. <source>Integr. Biol.</source> <volume>11</volume>, <fpage>186</fpage>&#x02013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1093/intbio/zyz017</pub-id><pub-id pub-id-type="pmid">31251339</pub-id></citation></ref>
<ref id="B178"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname> <given-names>X.-S.</given-names></name> <name><surname>Geng</surname> <given-names>W.-S.</given-names></name> <name><surname>Jia</surname> <given-names>J.-J.</given-names></name></person-group> (<year>2018</year>). <article-title>Neurotoxin-induced animal models of Parkinson disease: pathogenic mechanism and assessment</article-title>. <source>ASN Neuro</source> <volume>10</volume>:<fpage>1759091418777438</fpage>. <pub-id pub-id-type="doi">10.1177/1759091418777438</pub-id><pub-id pub-id-type="pmid">29809058</pub-id></citation></ref>
<ref id="B179"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>C.</given-names></name> <name><surname>Li</surname> <given-names>C.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Jia</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways</article-title>. <source>Redox Biol.</source> <volume>11</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2016.10.019</pub-id><pub-id pub-id-type="pmid">27835779</pub-id></citation></ref>
<ref id="B180"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>Z.</given-names></name> <name><surname>Klaunig</surname> <given-names>J. E.</given-names></name></person-group> (<year>2013</year>). <article-title><italic>Caenorhabditis elegans</italic> neuron degeneration and mitochondrial suppression caused by selected environmental chemicals</article-title>. <source>Int. J. Biochem. Mol. Biol.</source> <volume>4</volume>, <fpage>191</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="pmid">24380023</pub-id></citation></ref>
<ref id="B181"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>X.-X.</given-names></name> <name><surname>Zhong</surname> <given-names>Y.-Z.</given-names></name> <name><surname>Ge</surname> <given-names>Y.-W.</given-names></name> <name><surname>Lu</surname> <given-names>K.-H.</given-names></name> <name><surname>Lu</surname> <given-names>S.-S.</given-names></name></person-group> (<year>2018</year>). <article-title>CRISPR/Cas9-mediated generation of guangxi bama minipigs harboring three mutations in &#x003B1;-synuclein causing Parkinson&#x02019;s disease</article-title>. <source>Sci. Rep.</source> <volume>8</volume>:<fpage>12420</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-30436-3</pub-id><pub-id pub-id-type="pmid">30127453</pub-id></citation></ref>
<ref id="B182"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimprich</surname> <given-names>A.</given-names></name> <name><surname>Benet-Pag&#x000E8;s</surname> <given-names>A.</given-names></name> <name><surname>Struhal</surname> <given-names>W.</given-names></name> <name><surname>Graf</surname> <given-names>E.</given-names></name> <name><surname>Eck</surname> <given-names>S. H.</given-names></name> <name><surname>Offman</surname> <given-names>M. N.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease</article-title>. <source>Am. J. Hum. Genet.</source> <volume>89</volume>, <fpage>168</fpage>&#x02013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.008</pub-id><pub-id pub-id-type="pmid">21763483</pub-id></citation></ref>
<ref id="B183"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zirin</surname> <given-names>J.</given-names></name> <name><surname>Hu</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>L.</given-names></name> <name><surname>Yang-Zhou</surname> <given-names>D.</given-names></name> <name><surname>Colbeth</surname> <given-names>R.</given-names></name> <name><surname>Yan</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Large-scale transgenic <italic>Drosophila</italic> resource collections for loss- and gain-of-function studies</article-title>. <source>Genetics</source> <volume>214</volume>, <fpage>755</fpage>&#x02013;<lpage>767</lpage>. <pub-id pub-id-type="doi">10.1534/genetics.119.302964</pub-id><pub-id pub-id-type="pmid">32071193</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn id="fn0001"><p><sup>1</sup><ext-link ext-link-type="uri" xlink:href="https://cgc.umn.edu/">https://cgc.umn.edu/</ext-link></p></fn>
<fn id="fn0002"><p><sup>2</sup><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">http://zfin.org/</ext-link></p></fn>
</fn-group>
</back>
</article>